Vaccines and Global Health: The Week in Review
05 March 2022 :: Issue 647
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Emergencies
:: Organization Announcements
:: Journal Watch
WHO - Ukraine Emergency

WHO is working closely with our offices in Ukraine and neighbouring countries, as well as partners to rapidly respond to the health emergency triggered by the conflict and to minimize disruptions to the delivery of critical healthcare services.

WHO continues to deliver much-needed support on urgent health needs. During the crisis, health must remain a priority pillar, with health workers being protected so they can continue to save lives and with health systems and facilities being protected so that they remain functional, safe and accessible to all who need essential medical services. It is imperative to ensure that life-saving medical supplies – including oxygen – reach those who need them.

Emergency in Ukraine – Situation Report 1
5 March 2022 | Emergency Situational Updates
[Excerpts]

Priority public health concerns
- Conflict related trauma and injuries exacerbated by lack of access to health facilities by patients and health staff due to insecurity and lack of access to lifesaving medicine and supplies.
- Excess morbidity and death from common illnesses due to disruption in services such as non-communicable diseases (cardiovascular, diabetes, cancer etc.) and acute maternal, newborn and child illnesses.
- Spread of infectious diseases such as COVID-19, measles, polio, TB, HIV and diarrheal diseases due to widespread destruction of water and sanitation infrastructure, inadequate vaccination coverage, lack of access to medicines and medical care, safe water, adequate sanitation and hygiene as well as population movements and crowding.
- Mental health and psychosocial health - due to significant stress due to acute conflict and two years of COVID-19.

2.3. Epidemic prone and other infectious diseases

Recent outbreaks of polio and measles threaten the health of populations with suboptimal vaccination coverage (80% and 82% respectively in 2021), and the prevalence of HIV and tuberculosis, including multidrug resistant tuberculosis, are among the highest in Europe. Urgent actions are to restart or continue preventive measures through vaccination and continued treatment for TB and HIV and to scale up surveillance, early detection and response systems for epidemic-prone diseases.

A polio outbreak (circulating vaccine-derived poliovirus type 2) was confirmed in the country in 2021, with two paralytic cases (detected in October and December 2021), and a total of 21 individuals in two
oblachts (Rivne and Zakarpattya) who had positive isolation of cVDPV2 in stool specimens. As a result, a nationwide vaccination campaign targeting all under-vaccinated children (those having only zero or one dose) aged between 6 months and 6 years that began in February 2022. This campaign has been suspended because of the conflict, increasing the risk of further spread.

Over 240,000 weekly cases and 1300 deaths were reported for COVID-19 in the week 21-27 February. While this is a 43% decrease in cases compared to the previous week, testing rates have also declined sharply since the start of the conflict, with a likely significant undetected ongoing transmission. The ongoing high incidence levels of COVID-19 poses a significant risk of severe disease and death, particularly given the low vaccination coverage in at-risk population groups. Critical shortages of oxygen further impact on the ability to treat patients with severe COVID-19, and many other conditions. Beds occupied by COVID-19 patients were repurposed for trauma injuries and critical illnesses.

Figure 1. Population movement and displacement of refugees from Ukraine to surrounding countries as of 3 March 2022

Emergency appeal - Ukraine and neighbouring countries
2 March 2022

U.S. Treasury Prohibits Transactions with Central Bank of Russia and Imposes Sanctions on Key Sources of Russia’s Wealth
Press Release  
February 28, 2022  
- In Coordination with Allies and Partners, Treasury Actions Restrict Access to Billions in Central Bank Assets and Sovereign Wealth Fund  
- Treasury Sanctions Russian Direct Investment Fund – A Symbol of Russian Kleptocracy  
- United States and its Partners and Allies Continue to Hold the Government of the Russian Federation Accountable for its Premeditated and Unprovoked Invasion of Ukraine  

:::  

RDIF statement  
Press release, 28.02.2022  
The Russian Direct Investment Fund (RDIF, the sovereign wealth fund of the Russian Federation) was never involved in any political activities, does not interact in any way with Ukraine and follows the world’s best investment practices, which has been acknowledged by all its international partners as well by national regulators. RDIF always fully complies with laws of the countries where it conducts its investments.  

Imposition of sanctions against RDIF, which from the moment it was established has stood for building international relations and supporting constructive ties, demonstrates that the U.S. has picked the course to destroy constructive dialogue between countries.  

In the past two years, the Fund has been focusing on ensuring global epidemiological safety through its pivotal involvement in struggle against the new coronavirus infection in over 70 countries. In particular, RDIF is the key investor in unique test systems to detect coronavirus infection, anti-COVID medicine as well as in Russian vaccines Sputnik V and Sputnik Light, saving millions of lives by supplying vaccines and facilitating their production in Russia and other countries.  

The restrictions imposed by the U.S. authorities complicating RDIF efforts on the international promotion of the Russian vaccine products, have been lobbied by a number of large Western pharmaceutical companies. As a result of such unfair competition, billions of people around the world may be deprived of access to effective and safe Russian-made vaccines....  

:::  

European Commission suspends cooperation with Russia on research and innovation  
Press release  4 March 2022  
Following the Russian invasion against Ukraine and in solidarity with the people of Ukraine, the Commission has decided to suspend the cooperation with Russian entities in research, science and innovation. The Commission will not conclude any new contracts nor any new agreements with Russian organisations under the Horizon Europe programme. Furthermore, the Commission is suspending payments to Russian entities under existing contracts. All ongoing projects, in which Russian research organisations are participating, are being reviewed – both under Horizon Europe and Horizon 2020, the previous EU programme for research and innovation.  

Margrethe Vestager, Executive Vice-President for a Europe fit for the Digital Age, said: “EU research cooperation is based on the respect for the freedoms and rights that underpin excellence and
innovation. Russia’s heinous military aggression against Ukraine is an attack against those same values. It is therefore time to put an end to our research cooperation with Russia.”…

... Ukrainian scientists and researchers are key participants in our EU Framework programmes for R&I and have demonstrated excellence and innovation leadership across many fields. We are strongly committed to ensuring a continued successful participation of Ukraine and Ukrainian entities in Horizon Europe and Euratom Research and Training programmes...

The full statement of Commissioner Gabriel is available here. The assessment of the situation as regards Belarus is ongoing.

::::::
::::::
::::::

Malaria

First-ever malaria vaccine recommendation now published in a position paper and in the WHO guidelines for malaria
4 March 2022  Departmental news

WHO today published an updated position paper on the RTS,S/AS01 (RTS,S) malaria vaccine that includes the October 2021 recommendation calling for the wider use of the vaccine among children living in areas of moderate-to-high P. falciparum malaria transmission. The paper complements the recent addition of the recommendation to the WHO Guidelines for malaria.

“The first malaria vaccine is a major step forward for malaria control, child health and health equity. If implemented broadly, the vaccine could save tens of thousands of lives each year,” said Dr Kate O’Brien, director of the Department of Immunization, Vaccines and Biologicals. “This guidance is essential to countries as they consider whether and how to adopt the vaccine as an additional tool to reduce child illness and deaths from malaria,” she added.

…Coming soon: additional malaria vaccine tools for countries

This newly published guidance will be followed in the coming months by additional tools and information to guide countries that have decided to adopt the malaria vaccine – including a new malaria vaccine introduction guide and an operational manual for sub-national tailoring of malaria control tools…

Malaria vaccine: WHO position paper – March 2022
4 March 2022

Overview

This position paper supersedes the 2016 publication, “Malaria vaccine: WHO position paper-2016.” It includes the updated WHO recommendations on the wider use of the RTS,S/AS01 vaccine for the reduction of malaria morbidity and mortality in children living in areas of moderate to high malaria transmission. It also incorporates findings from the evaluation of the WHO-coordinated Malaria Vaccine Implementation Programme (MVIP), recommended by SAGE and MPAG in 2015, and from additional studies since 2015.

This paper does not include findings on vaccine efficacy in infants first vaccinated at 6–12 weeks of age. Because of the lower vaccine efficacy observed in this age category, WHO did not recommend pilot implementation or RTS,S/AS01 vaccine introduction for these young infants. Recommendations on the use of RTS,S/AS01 vaccine were discussed by SAGE and MPAG during a joint session in October
Workshop on WHO policy guidance on malaria elimination and the implementation of the intensification plans for reducing malaria burden in the Greater Mekong subregion
Virtual meeting, 22–23 November 2021
1 March 2022
Overview
The Workshop was convened virtually from 22 to 23 November 2021. Organized by the Mekong Malaria Elimination (MME) programme, it brought together participants from the 6 GMS countries – Cambodia, China, the Lao People’s Democratic Republic, Myanmar, Thailand and Viet Nam – and the Global Malaria Programme, as well as technical experts and partners to help GMS countries with the task of eliminating malaria and prepare them for the process of verification and certification of malaria.

AMR

Reducing Antimicrobial Discharges from Food Systems, Manufacturing Facilities and Human Health Systems into the Environment
Call to Action by the Global Leaders Group on Antimicrobial Resistance
March 2022
Disposal of untreated or inappropriately managed waste and runoff from various sources including food systems, manufacturing facilities and human health systems can contain biologically active antimicrobials, antimicrobial resistant organisms, unmetabolized antimicrobials and antimicrobial resistance determinants (e.g. resistance-conferring genes) that are released into the environment.

These discharges can contaminate the environment and contribute to the spread of antimicrobial resistance (AMR). The most important approach to controlling AMR spread from food systems and human health systems is responsible and sustainable use of antimicrobials in humans, terrestrial and aquatic animals and plants/crops. In addition, adequate measures to treat and safely dispose of waste are required, including human, animal and manufacturing waste.

The GLG commends ongoing efforts – particularly by the G7 countries – to address antimicrobial discharges into the environment and encourages countries to implement the Codex Code of practice to minimize and contain foodborne AMR and Guidelines on Integrated Monitoring and Surveillance of Foodborne Antimicrobial Resistance approved in November 2021.

To improve the management of discharges into the environment that may contribute to the emergence and spread of antimicrobial resistance, the Global Leaders Group calls for the following:

1. STRENGTHENED GOVERNANCE AND OVERSIGHT
In general, countries should:
   - Develop or build on and implement regulatory frameworks, guidelines, standard operating procedures (SOPs) and standards to establish safe levels, better control and monitor the distribution and release of antimicrobials, antimicrobial resistant bacteria and antimicrobial
resistance determinants from food systems, manufacturing facilities and human health systems into the environment; and
- Include prevention and management measures in national action plans on AMR to minimize the impacts of environmental discharges.

**In the manufacturing sector** specifically, countries should:
- Develop and implement legal and policy frameworks with a lifecycle approach for antimicrobials manufacturing. Such an approach considers the entire timespan that a pharmaceutical is active and can impact the surrounding systems, would help to effectively address AMR environmental risks and ensure resilient antibiotic supply chains and stimulate the design, development, manufacture, and commercialization of needed new antibiotics and alternatives to antimicrobials;
- Promote and develop balanced and staged environmental policies and approaches to manage and regulate manufacturing facilities and support environmental inspections, recognizing the current fragility of supply chains and significant access gaps;
- Incentivize industry for compliance and excellence, including highlighting their contribution to the achievement of the Sustainable Development Goals; and
- Develop national antimicrobial manufacturing pollution standards based on best available evidence, treatment technology and situational analysis, and strengthen the capacity of environmental authorities to conduct audits and monitor compliance.

**In the human health sector** specifically, countries should:
- Develop and implement antimicrobial stewardship policies and protocols in human health systems that include responsible and sustainable use and procurement of antimicrobials, and effective waste management approaches; and
- Implement and enforce laws and policies to reduce or eliminate antimicrobial use that is not under the guidance of a trained health care provider, while ensuring equitable access to quality antimicrobials.

**In food systems** specifically, countries should:
- Develop or build on and implement regulatory frameworks, guidelines, SOPs and standards to effectively treat and/or manage waste discharge from food-producing animal farms, aquaculture farms and crop fields, as well as waste used to irrigate crops and run-off from crop fields; and
- Develop and implement antimicrobial stewardship policies and protocols in fixed and mobile animal health facilities that include responsible and sustainable use of antimicrobials and effective waste management approaches.

**2. IMPROVED SURVEILLANCE AND DATA AVAILABILITY**

Countries should:
- Strengthen One Health surveillance of antimicrobial use in, and discharges of antimicrobials and AMR determinants from, food systems, human health systems and manufacturing facilities, as well as in sewage systems. This should be done taking into account factors such as the need to build on existing systems, cost-effectiveness, data comparability and key knowledge gaps relating to the fate, concentration and impact of discharges on the environment and organisms in the environment (e.g. soil microbes, aquatic organisms). Priority should be given to collecting data that can support targeted action, such as enhanced understanding of risks to human and animal health and the environment and release pathways into the environment, and supporting
the development of guidance on waste management approaches and antimicrobial discharge limits; and
- Promote industry data disclosure, transparency and public access to waste and wastewater management data and mitigation practices in order to build credibility and public confidence. Data disclosure could initially be made to regulators and independent third parties (for example as part of certification schemes), followed by efforts to enable wider public access to increase awareness and understanding, contribute to ongoing studies and reflect environmental standards in procurement practices.

3. IMPROVED DISCHARGE MANAGEMENT

In general, all countries should:
- Reduce the need for antimicrobial use through implementation of effective infection prevention and control measures in all sectors, including water, sanitation and hygiene (WASH), vaccination, biosecurity and animal husbandry and welfare measures;
- Develop, implement and monitor systems for proper segregation, treatment and/or disposal of antimicrobials and antimicrobial-containing substances in all sectors (including antimicrobial feed and human and animal waste);
- Develop mechanisms for collection and proper disposal of unused and expired antimicrobials from individuals and organizations; and
- Ensure availability of affordable and environmentally safe incinerators and innovative technologies for destruction and degradation of unused or expired antimicrobials.

In general, relevant international technical organizations and their partners should develop guidance and showcase best practices on proper waste management practices across sectors.

In food systems:
All countries should:
- Create and implement manure, wastewater, runoff and farm waste management plans, SOPs, guidance, standards and measures such as composting for manure and its application into agriculture fields; and
- Implement evidence-based manure management approaches so that manure can continue to be safely used as a natural fertilizer in agriculture fields and support agro-ecological farming practices while minimizing the risks of transfer of antimicrobial resistant bacteria or antimicrobial resistance determinants.

International technical organizations should:
- Expedite the development of tools and guidance to support the implementation of the Codex Code of practice to minimize and contain foodborne AMR and Guidelines on Integrated Monitoring and Surveillance of Foodborne Antimicrobial Resistance along the food chain (e.g. food processing and production facilities, wet markets, slaughterhouses) to minimize the impacts of antimicrobial discharge into the environment.

Companies involved in the slaughter and processing of food animals should:
- Assess current food production practices to implement measures to reduce discharges of by-products, including biocides, into the environment and comply with legal standards and requirements.

In the manufacturing sector:
Manufacturing companies should:
- Commit to prevention and management measures to minimize the impacts of manufacturing discharges into the environment. This can be done through effective waste management technologies and practices, adoption and implementation of the common antibiotic manufacturing framework and the proposed independent certification schemes of the AMR Industry Alliance.

All stakeholders should:
- Evaluate options and support efforts to create an enabling environment that influences and supports investment through incentives and efforts in pharmaceutical waste management without jeopardizing access to antimicrobials. Such evaluations may include an assessment of sustainable procurement policies, inclusion of environmental considerations in good manufacturing practices, environmental risk assessment before antimicrobial authorization and an independent product-certification scheme.

4. RESEARCH AND DEVELOPMENT
International technical, financing and research and development organizations and partners should:
- Enhance and coordinate research for a comprehensive understanding of risks to human and animal health from the environmental presence of antimicrobials, resistance microbes and mobile genetic elements in discharges, as well as potential hot spots, environmental impacts and antimicrobial resistance pathways, and mitigation measures;
- Promote research and development across public and private sectors into cost-effective and greener waste management technologies including methods to remove antimicrobial residues, resistance genes and resistant organisms and other tools (e.g., climate-sensitive incinerators and measurement technologies) and standardized monitoring methods, and support mainstreaming of best practices in process and waste management across sectors; and
- Develop policy briefs on antimicrobial resistance and organize policy dialogues among policymakers to support evidence-based policymaking.

Global Leaders Group on Antimicrobial Resistance background
The Global Leaders Group on Antimicrobial Resistance was established in November 2020 and performs an independent global advisory and advocacy role with the primary objective of maintaining urgency, public support, political momentum and visibility of the AMR challenge on the global agenda. The mission of the group is to collaborate globally with governments, agencies, civil society and the private sector through a One Health approach to advise on and advocate for political action for the mitigation of drug-resistant infections through responsible and sustainable access to and use of antimicrobials.

The group is co-chaired by Their Excellencies Sheikh Hasina, Prime Minister of Bangladesh and Mia Amor Mottley, Prime Minister of Barbados and is composed of heads of state, serving or former ministers and/or senior government officials acting in their individual capacities, together with senior representatives of foundations, civil society organizations and the private sector. It also includes principals of the Tripartite organizations – the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE) and the World Health Organization (WHO), and the UN Environment Programme (UNEP) – in an ex-officio capacity. The Tripartite Joint Secretariat (TJS), a joint effort by FAO, OIE and WHO, and UNEP, provides Secretariat support for the Group.
COVID - Therapeutics

Therapeutics and COVID-19: living guideline - WHO
3 March 2022

Overview
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, and is updated regularly as new evidence emerges.

This ninth version of the WHO living guideline now contains 15 recommendations, including one new recommendation regarding use of molnupiravir. Two updates have been made to previous existing recommendations were made in this latest version....

:: ** NEW ** conditional recommendation for use of Molnupiravir for patients with non-severe COVID-19, conditional for those at highest risk of hospitalization (excluding pregnant or breastfeeding women, and children) (published 03 March 2022);

::::

Unitaid statement on WHO guidelines for COVID-19 antiviral molnupiravir
03 March 2022

Geneva – Unitaid today welcomes the conditional recommendation from the World Health Organization (WHO) on the use of molnupiravir to treat adult patients with mild to moderate COVID-19 at highest risk of developing severe forms of the disease.

Oral outpatient treatments are potential gamechangers in the management of COVID-19. They are critical in the global response to the pandemic, with a potential to save lives and ease the pressure on healthcare systems, and an important step toward realizing the promise of test-and-treat strategies in decentralized settings.

Molnupiravir is the first oral antiviral for non-hospitalized mild-to-moderate COVID-19 patients to be recommended by WHO, bringing an additional treatment option to the COVID-19 clinical care package...

::::

COVID - ACT-Accelerator

ACT-Accelerator welcomes Germany’s generous ‘fair share’ commitment
1 March 2022

Statement
Germany has become the first country to pledge to meet its ‘fair share’ of the ACT-Accelerator’s 2021/22 budget, with a generous contribution of US$ 1.22 billion towards the partnership’s vital work on access to COVID-19 treatments, tests, vaccines, and personal protective equipment.

Last month, President Ramaphosa of South Africa and Prime Minister Støre of Norway – in their roles as co-chairs of the ACT-Accelerator Facilitation Council - made a call to 55 countries to jointly support global efforts to end the COVID-19 crisis and contribute their ‘fair share’ to the ACT-Accelerator agencies’ US$ 16.8 billion urgent needs and end the COVID-19 crisis.
‘Fair shares’ are calculated based on the size of a country’s national economy and what they would gain from a faster recovery of the global economy and trade.

The pledge - announced by Finance Minister Christian Lindner at the G7 Finance Ministers’ Meeting today - takes Germany to its ‘fair share’ ask for this budget cycle and is accompanied by an additional US$ 253 million for supplementary measures for the in-country COVID-19 response, complementary to the ACT-A mission...Germany also exceeded its fair share for the 2020/21 budget cycle with US$ 2.5 billion provided across all of the ACT-Accelerator's areas of work, a vital contribution to saving lives, protecting health systems and reducing the evolution of dangerous new variants...

COVID - Global Immunization Targets

Analysis: Is WHO's aim to vaccinate 70% of world by June still realistic?
Reuters February 28, 2022
By Jennifer Rigby
LONDON, Feb 28 (Reuters) - Vaccinating 70% of the population in every country in the world against COVID-19 by mid-2022 has been the World Health Organization's (WHO) rallying cry to end the pandemic.

But recently, public health experts say that while boosting immunity globally remains essential, the figure is neither achievable nor meaningful.

It has always been ambitious: Currently, just 12% of people in low-income nations have had one shot, according to Our World In Data. Earlier targets set by WHO – to reach 10% by September 2021, for example – were also missed.

WHO head of immunization Kate O'Brien said 70% remained more than just a "rallying cry", even though some well-equipped countries with plenty of vaccines have also struggled to reach it. "We are calling for countries to be serious about their actions towards achieving that target, while acknowledging that - on a country-by-country basis - there may be a rationale why that target is not specifically suited to that country," she told Reuters.

Gavi, the Vaccine Alliance - WHO's partner in the COVAX initiative aimed at getting shots to the world's poorest – has pulled back from the "one-size-fits-all" 70% focus. At a virtual briefing last week with WHO Africa, Aurelia Nguyen, managing director of COVAX within Gavi, said it was important to instead "meet the targets that countries have set for themselves, whether it's in line with the 70% WHO target or a lower or a higher target."

Reservations about the 70% target are a further sign that ending the pandemic globally may be a trickier, and longer, challenge than many had hoped. Documents from a high-level internal UN meeting held earlier this month, reviewed by Reuters, showed eight countries that were extremely unlikely to reach the target by June 2022, and had been identified for "immediate focus": Afghanistan, the Democratic Republic of Congo, Ethiopia, Ghana, Kenya, Nigeria, Sierra Leone and Sudan. A further 26, including Yemen, Uganda and Haiti, are also in need of "concerted support", the document said.
NEVER JUST A MAGIC NUMBER

However, there is a bigger issue the WHO is focusing on O'Brien said. "The question in the here and now, with Omicron ripping through the population around the world and continuing to do that ... does 70% still hold?" she said. The figure was never a "magic number", she said, but just an assessment of risk, something to aim for that could – optimistically – keep the virus under control.

But new evidence showing that the vaccines only have a limited impact on transmission, alongside the ability of the Omicron variant to infect previously vaccinated or infected people, suggests that achieving that level of population immunity and therefore stopping the spread of the virus is a fading hope.

"We are in the process of looking at scenarios of how the pandemic might play out", O'Brien said. "Obviously across the scenarios, the role of the vaccines, the target of the 70%, the goal of transmission reduction, would have to be evaluated.” For example, setting higher targets among at-risk groups may be important to prevent hospitalisations and deaths, she added.

But some public health experts said the initial target was now largely symbolic. Edward Kelley, former director of health services at WHO and now global health officer at ApiJect, said the 70% had been based on what science said was needed to manage transmission, which had been blown out of the water by Omicron. "Of course we need to continue to raise immunity levels everywhere", he said. "But the target is being kept at the moment because the international community does not have anything else to cling to."...

---

Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 25 Feb 2022
Confirmed cases :: 440 807 756
Confirmed deaths :: 5 978 096
Vaccine doses administered: 10 585 766 316

Weekly epidemiological update on COVID-19 - 1 March 2022
Overview
Globally, during the week of 21 through 27 February 2022, the number of new COVID-19 cases and deaths continued to decline by 16% and 10% respectively, as compared to the previous week. Across the six WHO regions, over 10 million new cases and over 60 000 new deaths were reported. As of 27 February 2022, over 433 million confirmed cases and over 5.9 million deaths have been reported globally.
At the regional level, the Western Pacific Region reported a 32% increase in the number of new weekly cases while all other regions reported decreases. The number of new weekly deaths increased
in the Western Pacific (+22%) and the Eastern Mediterranean (+4%) Regions, whilst a decreasing trend have been reported by the Regions of Africa (-59%), South-East Asia (-18%), Europe (-13%) and Americas (-8%).

In this edition, we provide updates on the geographic distribution of circulating SARS-CoV-2 variants of concern (VOCs), including the spread and prevalence of the Omicron variant.

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 27 February 2022**

**See Annex 2: Data, table, and figure notes

WHO Director General Speeches  [selected]
https://www.who.int/director-general/speeches

Selected
3 March 2022
Speech
WHO Director-General's remarks at Session 2 – Potential Opportunities for Innovation and Collaboration COVID-19 Dialogue with Ministers of Health – 3 March 2022

3 March 2022
Speech
WHO Director-General's opening remarks at the Member State Information Session on COVID-19 – 3 March 2022

2 March 2022
Speech
WHO Director-General's opening remarks at the media briefing on COVID-19 – 2 March 2022
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 23 December 2021
[Full scale view available at title link above]
[Updated on 02 March 2022]

COVID Vaccines/Therapeutics - Developer/Manufacturer Announcements
[Selected press releases/announcements from organizations from WHO EUL/PQ listing above and other organizations]

AstraZeneca
Press Releases - No new digest announcements identified

Bharat Biotech
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias - Website not leading at inquiry

Biontech
Press Releases - No new digest announcements identified

CanSinoBIO
News - [Website not responding at inquiry]

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - Website not responding at inquiry

Gamaleya National Center
Latest News and Events - See Russia below and under Ukraine above

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Moderna
Press Releases - No new digest announcements identified

Novavax
Press Releases
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
Feb 28, 2022

Pfizer
Recent Press Releases
03.02.2022
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women

Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases
Brazilian Study: Due to the vaccination roll-out applied to elderly: 167,000 hospitalizations and 77,000 lives were avoided
2022/03/04

Vector State Research Centre of Viralology and Biotechnology
Home - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

::::::

GSK
Press releases for media
GSK provides further update on phase III RSV maternal vaccine candidate programme
28 February 2022

Merck
News releases -
Dr. Julie L. Gerberding to Retire from Merck
March 1, 2022
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. Julie L. Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from Merck in May 2022. Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16...

**Novartis**

*News* - No new digest announcements identified

**SK Biosciences**

*Press releases* - No new digest announcements identified

**Valneva**

*Press Releases*

March 1, 2022

Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated COVID-19 Vaccine VLA2001

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 05 Mar 2022

An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 10/22/2021 reported]

- 33 vaccines approved for use by at least one national regulatory authority
- 10 vaccines in WHO's Emergency Use Listing
- 17.5bn doses secured globally
- $2 - $40 reported vaccine price range per dose
- 2.8bn doses COVAX has secured from funded agreements and confirmed donations
- 1.34bn doses shipped through COVAX to 144 countries

**COVID-19 Global Targets and Progress Tracker** - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges. The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.
Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 05 Mar 2022]: [https://data.undp.org/vaccine-equity/](https://data.undp.org/vaccine-equity/)
See also visualization on [Vaccine Access](https://data.undp.org/vaccine-access/) and [Vaccine Affordability](https://data.undp.org/vaccine-affordability/)

---

Global COVID-19 Access Tracker
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution.

[accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
05 Mar 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 4410M total confirmed cases; 6.0M total confirmed deaths
Global vaccines administered: 10.7B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 260M
Other Delivered (Number of Doses): 250M
Total Delivered (Number of Doses): 520M
Total Administered (Number of Doses): 320M
https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.

The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Website accessed 05 Mar 2022: https://data.covid19taskforce.com/data. The global view below is complemented by country-specific dashboards here.

Our World in Data
Coronavirus (COVID-19) Vaccinations  [Accessed 05 Mar 2022]
- 63.2% of the world population has received at least one dose of a COVID-19 vaccine.
- 10.84 billion doses have been administered globally, and 22.03 million are now administered each day.
- Only 13% of people in low-income countries have received at least one dose.
Share of people who completed the initial COVID-19 vaccination protocol, Mar 4, 2022
Total number of people who received all doses prescribed by the initial vaccination protocol, divided by the total population of the country.

Source: Official data collated by Our World in Data - Last updated 5 March 2022, 11:20 (London time)
Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.
OurWorldinData.org/coronavirus • CC BY
White House [U.S.]  [to 05 Mar 2022]  
*Briefing Room – Selected Major COVID Announcements*

**National COVID-19 Preparedness Plan**
March 01, 2022

Today, the U.S. government is releasing the National COVID-19 Preparedness Plan – which will enable America to move forward safely, sustaining and building on the progress we've made over the past 13 months. This plan lays out the roadmap to help us fight COVID-19 in the future as we begin to get back to our more normal routines. We look to a future when Americans no longer fear lockdowns, shutdowns, and our kids not going to school. It’s a future when the country relies on the powerful layers of protection we have built and invests in the next generation of tools to stay ahead of this virus.

The President’s National COVID-19 Preparedness Plan focuses on four key goals:
First, protect against and treat COVID.
Second, prepare for any new variants.
Third, prevent economic and school shutdowns.
Fourth, vaccinate the world and save lives...

**Memorandum on Maximizing Assistance to Respond to COVID-19**
March 01, 2022 • Presidential Actions

afely, sustaining and building on the progress we’ve made over the past 13 months...
So I did travel as quickly as I could to the Ukrainian-Polish border. And we've been planning for -- around a number of scenarios for many months, prepositioning stockpiles, getting the organization the World Food Programme, which had been active in Ukraine back when the conflict broke out in Crimea in Eastern Ukraine, but then had gotten out about three years ago. Getting them to reestablish a presence there, knowing that a conflict unfortunately was likely, that a Russian invasion was likely. And so part of what I was up to was checking in with our DART team, with our team of forty people who are these kind of crack emergency responders that help coordinate among the various agencies. The flow of goods and people across border crossings along the front-line states...

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

News: Regulation on EMA’s extended mandate becomes applicable (new)

Last updated: 01/03/2022

The regulation reinforcing EMA’s role in crisis preparedness and management of medicinal products and medical devices becomes applicable as of today, 1 March 2022. It puts some of the structures and processes established by EMA during the COVID-19 pandemic on a more permanent footing, while entrusting several new tasks to the Agency.

EMA is now responsible for monitoring medicine shortages that might lead to a crisis situation, as well as reporting shortages of critical medicines during a crisis. The Agency will also coordinate responses of EU / EEA countries to shortages of critical medical devices and in-vitro diagnostics in crisis situations, after an initial transition period up to 2 February 2023.

Over the next few weeks and months, EMA will set up a number of new bodies and formalise existing ones to manage the new tasks...
Latest Updates [Selected]
No new digest content identified.

---

**European Centre for Disease Prevention and Control**

**COVID-19 Vaccine Tracker**

Cumulative vaccine uptake (%) in the total population in EU/EEA countries

<table>
<thead>
<tr>
<th>At least one dose</th>
<th>Primary course</th>
<th>Booster/additional dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>75.1%</td>
<td>71.9%</td>
<td>51.5%</td>
</tr>
</tbody>
</table>

Cumulative vaccine uptake (%) in the total population in EU/EEA countries as of 2022-03-04
by reporting week (data for the current week are preliminary)

*Accessed 05 Mar 2022*


---

**European Commission**


**Press release**  4 March 2022

*Commission suspends cooperation with Russia on research and innovation*

[See Ukraine above for detail]*

**Press release**  2 March 2022

*Ukraine: Commission proposes temporary protection for people fleeing war in Ukraine and guidelines for border checks*

Today, the Commission is proposing to activate the Temporary Protection Directive to offer quick and effective assistance to people fleeing the war in Ukraine.

**Press release**  2 March 2022

*EU budget: Commission publishes guidance on the conditionality mechanism*

Today the European Commission adopted its guidelines on the general regime of conditionality, which aims to protect the EU budget against breaches of the principles of the rule of law.

**Speech**  1 March 2022

*Speech by President von der Leyen at the European Parliament Plenary on the Russian aggression against Ukraine*

This is a moment of truth for Europe...
Africa: COVID-19 – Announcements/Regulatory Actions/Deployment


Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
RDIF statement
India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare
https://www.mohfw.gov.in/

Government of India – Press Information Bureau

Latest Press Releases

COVID - 19 Vaccination Update - Day 414
:: India’s cumulative vaccination coverage crosses 178.80 Crore
:: More than 23 lakh Vaccine doses administered today till 7 pm

Posted On: 05 MAR 2022 8:15PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html

Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[See China CDC below]

Emergencies

POLIO
Polio this week as of 23 February 2022

:: Amid the escalating crisis in Ukraine, the GPEI has expressed extreme concern about the unfolding effects of the conflict on the country’s health system as security and displacement increase risk of diseases such as polio. Read the statement.

:: Earlier this week, the Spanish Minister of Foreign Affairs officially announced his role as Polio Gender Champion during an event in Madrid, Spain. Read his statement and commitments together with those of other Gender Champions

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

– **Madagascar**: one cVDPV1 case
– **Nigeria**: two cVDPV2 positive environmental samples

**Djibouti launches national polio vaccination campaign**

Djibouti, 27 February 2022 - Djibouti’s Ministry of Health, with technical support from WHO and UNICEF, today kicked off a five-day national polio vaccination campaign aiming to reach all children in Djibouti aged zero to 59 months, approximately 150,000 children.

Multi-disciplinary teams of vaccinators, social mobilizers and technical experts are fanning out across the country to knock on every door, vaccinate every child under five and raise immunity levels to this deadly childhood disease. This is a house-to-house campaign, with vaccination also being offered in health facilities.

Djibouti was declared polio-free in 1999, but outbreaks of poliovirus type 2 in Ethiopia, Somalia and Yemen underscore the risk to all children in the Horn of Africa and the broader region...

Disease Outbreak News (DONs)

:: **3 March 2022 | Wild poliovirus type 1 (WPV1) - Malawi**

...Sequencing of the virus conducted by the NICD on 2 February, and the US CDC on 12 February confirmed this case as WPV1. Analysis shows that the current WPV1 isolate in Malawi is genetically linked to a Pakistan sequence detected in 2020 in Sindh province. Africa was declared free of indigenous wild polio in August 2020 after eliminating all forms of wild polio from the region, and in Malawi, the last clinically confirmed WPV case was reported in 1992...

WHO/OCHA Emergencies

**Health emergencies list - WHO**

“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

*Afghanistan crisis* [Last apparent update: 17 Jan 2022]
Crisis in Northern Ethiopia  [Last apparent update: 1 June 2021]


Ebola outbreak outbreak, N’Zerekore, Guinea, 2021  [Last apparent update: 17 Aug 2021]

Coronavirus disease (COVID-19) pandemic  [See COVID above]

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020
[Last apparent update: 17 Aug 2021]

Ebola outbreak, Democratic Republic of the Congo, 2018  [Last apparent update: 24 July 2018]

Yemen crisis  [Last apparent update: 12 February 2021]

Syria crisis  [Last apparent update: 18 June 2021]

Somalia crisis  [Last apparent update: 24 March 2018]

Nigeria crisis  [Last apparent update: 1 Oct 2021]


Zika virus disease outbreak, 2015-2016  [Last apparent update: 24 Jan 2020]


Iraq crisis  [Last apparent update: 9 Jan 2008]

South Sudan crisis  [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak  [Last apparent update: 13 September 2021]

Middle East respiratory syndrome (MERS-CoV) outbreak  [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic  [Last apparent update: 10 Aug 2010]

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
No new updates identified.
Northern Ethiopia

Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 3 March 2022

HIGHLIGHTS

- The humanitarian situation in Afar continues to deteriorate with increased displacement and needs.
- Nutrition supplies for the treatment of severe acute malnutrition among young children airlifted to Tigray, for the first-time since mid-December.
- No food distribution reported in Tigray between 17 and 23 February, as food and fuel in the region is almost entirely exhausted.
- More than 283,000 people assisted with food during the reporting week in Dessie and Kombolcha towns and in North Gondar Zone by the UN and INGO partners.
- A new food distribution cycle has started in Afar targeting more than 622,000 people with more than 18,000 people reached during the week in Yalo, Abala, Barahle and Megale woredas.

WHO & Regional Offices [to 05 Mar 2022]

https://www.who.int/

News [Selected]

4 March 2022

Departmental news

First-ever malaria vaccine recommendation now published in a position paper and in the WHO guidelines for malaria

[See Perspectives above for detail]

3 March 2022

News release

WHO updates its treatment guidelines to include molnupiravir

3 March 2022

Statement

WHO and MPP welcome NIH’s offer of COVID-19 health technologies to C-TAP

2 March 2022

Departmental news

World leaders and experts call for action to protect the environment from antimicrobial pollution

[See Perspectives above for detail]

2 March 2022

News release

COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide

Scientific brief: Mental health and COVID-19: Early evidence of the pandemic’s impact

1 March 2022
Statement

**ACT-Accelerator welcomes Germany’s generous ‘fair share’ commitment**

[See Perspectives above for detail]

27 February 2022

**Departmental news**

**Singapore medicines regulator world’s first to achieve highest maturity level in WHO classification**

Out of 28 countries formally assessed by WHO, Singapore is the first to have achieved the highest maturity level (ML 4) in WHO’s classification of regulatory authorities for medical products. Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference...

Regulation of medical products is extremely important for all health systems and for access to quality vaccines, medicines and other health products. Apart from ensuring the quality, safety and efficacy of medical products, regulatory authorities that function well also perform critical functions such as faster authorization of products and drug safety monitoring after authorization.

WHO’s assessment of regulatory authorities is based on the ‘Global Benchmarking Tool’ – an evaluation tool that checks regulatory functions against a set of more than 260 indicators – covering core regulatory functions such as product authorization, testing of products, market surveillance and the ability to detect adverse events – to establish their level of maturity and functionality. Regulatory authorities that reach maturity levels 3 and 4 will be considered eligible for inclusion among WHO-listed authorities, after additional evaluation of their performance...

27 February 2022

**Statement**

**Dangerously low medical oxygen supplies in Ukraine due to crisis, warn WHO Director-General and WHO Regional Director for Europe**

::::::

**WHO Regional Offices**

Selected Press Releases, Announcements

**WHO African Region**

:: 04 March 2022 [Malawi intensifies response after wild poliovirus detected]
:: 04 March 2022 [Rallying to combat COVID-19 rumours in the Democratic Republic of the Congo]
:: 02 March 2022 [Obesity rising in Africa, WHO analysis finds]

**WHO Region of the Americas** PAHO

:: [A third of pregnant women with COVID-19 unable to access life-saving critical care on time]
2 Mar 2022  In the Americas, over 365,000 pregnant women got COVID-19 and more than 3000 died. Ahead of International Women’s Day, PAHO Director urges countries to invest in improving access to vaccines and essential care for women and girls. Washington D.C. 2 March 2022 (PAHO) – A lack of access to timely care and disruptions to prenatal services are to...
:: [COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide]
2 Mar 2022  Wake-up call to all countries to step up mental health services and support Geneva, 2 March 2022 – In the first year of the COVID-19 pandemic, global prevalence of anxiety and depression increased by a massive 25%, according to a scientific brief released by the World Health Organization (WHO) today. The brief also highlights who has been most...
WHO releases new standard to tackle rising threat of hearing loss
Geneva, 2 March 2022 – Over 1 billion people aged 12 to 35 years risk losing their hearing due to prolonged and excessive exposure to loud music and other recreational sounds. This can have devastating consequences for their physical and mental health, education, and employment prospects. Ahead of World Hearing Day 2022, under the theme To...

PAHO initiates procedures to elect next Director
1 Mar 2022  Election will take place during the 30th Pan American Sanitary Conference in September 2022, and countries may nominate candidates until May 1, 2022. Washington, D.C., March 1, 2022 (PAHO/WHO) - The process to elect the next Director of the Pan American Sanitary Bureau (PASB) officially began this week with a formal invitation by the President of...

WHO South-East Asia Region SEARO
No new digest content identified

WHO European Region EURO
:: Ukraine’s most vulnerable children in a Kherson home, designed to keep them safe and healthy 05-03-2022
:: Running a hospital while your country is under attack – a story from western Ukraine 01-03-2022

WHO Eastern Mediterranean Region EMRO
:: Nearly 18 000 Yemenis with genetic blood disorders receive lifesaving medications under IsDB-funded WHO programme 1 March 2022
:: WHO delivers SARS-CoV-2 kits for research at Tehran’s Pasteur Institute 28 February 2022
:: Djibouti launches national polio vaccination campaign 27 February 2022

WHO Western Pacific Region
No new digest content identified

WHO Events
https://www.who.int/news-room/events/2
[Selected]
Immunization and vaccines related implementation research advisory committee (IVIR-AC) - March 2022
7 – 11 March 2022

New WHO Publications
https://www.who.int/publications/i
Selected Titles
4 March 2022
Malaria vaccine: WHO position paper – March 2022

3 March 2022
Therapeutics and COVID-19: living guideline
2 March 2022
Mental Health and COVID-19: Early evidence of the pandemic’s impact: Scientific brief, 2 March 2022

2 March 2022
Tuberculosis prevention and care among refugees and other populations in humanitarian settings: an interagency field guide

Overview
Tuberculosis (TB) remains one of the leading infectious diseases causing millions to fall ill and lose their lives annually. Refugees and other populations in humanitarian settings face substantial threats to health and survival, such as poverty, crowded living conditions, undernutrition and poor access to health services – all conditions in which TB transmission thrives.

This guide is a joint effort of the Centers for Disease Control and Prevention (CDC), the UN High Commissioner for Refugees (UNHCR) and the World Health Organization (WHO). It includes new strategic approaches, guidance and innovations for TB prevention and care interventions in humanitarian settings. The guide focuses primarily on managerial/organizational aspects of TB interventions, and provides links to the most updated references for the clinical aspects. We hope this guide can serve as a useful tool in humanitarian settings to alleviate the suffering and deaths caused by this preventable and curable disease, especially for refugees and displaced populations in humanitarian settings.

1 March 2022
Workshop on WHO policy guidance on malaria elimination and the implementation of the intensification plans for reducing malaria burden in the Greater Mekong subregion
Virtual meeting, 22–23 November 2021

28 February 2022
Information for applicants preparing a submission for the 2023 meeting of the WHO Expert Committee on Selection and Use of Essential Medicines

28 February 2022
Continuum of care for noncommunicable disease management during the migration cycle

28 February 2022
Primary health care measurement framework and indicators: monitoring health systems through a primary...

28 February 2022
WHO implementation handbook for national action plans on antimicrobial resistance: guidance for the human...

CDC/ACIP [U.S.] [to 05 Mar 2022]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Latest News Releases, Announcements [Selected]
No new digest content identified.

ACIP Meetings
Next meeting scheduled for June 22-23, 2022

MMWR News Synopsis  Friday, March 3, 2022
- Geospatial Transmission Hotspots of Recent HIV Infection in Malawi, October 2019–March 2020
- Previously Released: SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022
- Previously Released: Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

Coronavirus Disease 2019 (COVID-19)- CDC
Approximately 25 announcements/reports/data summaries.
:: 3/4/22  Overall US COVID-19 Vaccine Distribution and Administration Update as of Fri, 04 Mar 2022 06:00:00 EST

Africa CDC  [to 05 Mar 2022]
http://www.africacdc.org/
News
Global Afropop star Yemi Alade urges vaccination in Africa
4 March 2022

China CDC  http://www.chinacdc.cn/en/
National Health Commission of the People's Republic of China  [to 05 Mar 2022]
http://en.nhc.gov.cn/
News
March 5: Daily briefing on novel coronavirus cases in China
On March 4, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 281 new cases of confirmed infections.

**National Medical Products Administration – PRC** [to 05 Mar 2022]

http://english.nmpa.gov.cn/

*News*

**Over 3.14b COVID-19 vaccine doses administered on Chinese mainland**

2022-03-04

The number of COVID-19 vaccine doses administered on the Chinese mainland grew by around 5.88 million from the previous day to surpass 3.14 billion on Wednesday, data from the National Health Commission showed on March 3.

**CCDC Weekly Reports: Current Volume (4)**

2022-03-04 / No. 9  **SIXTH TOTAL DIET STUDY ISSUE**

**Contents [click to move among sections]**

:: Coronavirus [COVID-19] - WHO

:: Emergencies

:: Organization Announcements

:: Journal Watch

**Milestones - Perspectives**

:: Coronavirus [COVID-19] - WHO

:: Emergencies

:: Organization Announcements

:: Journal Watch

**Organization Announcements**

_Editor’s Note:_

Careful readers will note that the number and range of organizations now monitored in our _Announcements_ section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.
INSIGHTS & COMPANY NEWS
No new digest content identified.

Paul G. Allen Frontiers Group [to 05 Mar 2022]
https://alleninstitute.org/news-press/
News

News from the Allen Institute: March 2022
March 2, 2022
Highlights include: our 2021 annual report, announcing our incoming President and CEO Rui Costa, 23 Allen Distinguished Investigators announced, upcoming events and more.

BMGF - Gates Foundation [to 05 Mar 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 05 Mar 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X [to 05 Mar 2022]
https://carb-x.org/
News
No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 05 Mar 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Informed Consent: A Monthly Review – March 2022 is now posted here
:: Past weekly editions and posting of all segments of Vaccines and Global Health: The Week in Review are available here.
:: Statement on ICF [Informed Consent Form] Posting for Clinical Trials Involving Gene Editing/Gene Therapies - Invitation to Endorse

CEPI – Coalition for Epidemic Preparedness Innovations [to 05 Mar 2022]
DARPA – Defense Advanced Research Projects Agency [U.S.] [to 05 Mar 2022]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 05 Mar 2022]
https://dukeghic.org/
Our Blog
No new digest content identified.

EDCTP [to 05 Mar 2022]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
News
No new digest content identified.

Emory Vaccine Center [to 05 Mar 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 05 Mar 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

Evidence Aid [to 05 Mar 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
New Resources
Barriers and facilitators affecting HIV care for migrant people living with HIV in Organization for Economic Co-Operation and Development (OECD) countries Added March 4, 2022
Health impact and risk factors affecting women in south and southeast Asia following disasters caused by natural hazards Added March 2, 2022

Clinical practice guidelines for pharmacologic treatments of hospitalized COVID-19 patients: assessment of quality and trustworthiness (search up to 28 February 2021) Added February 28, 2022

Fondation Merieux [to 05 Mar 2022]
http://www.fondation-merieux.org/
News, Events
Mérieux Foundation co-organized event
7th Meeting of the GTFCC Working Group on WASH
March 9 - 10, 2022 - Hybrid Event - Virtual & Les Pensières Center for Global Health, Veyrier-du-Lac (France)
The 7th Meeting of the Global Task Force for Cholera Control (GTFCC) Working Group on WASH will be held from March 9-10, 2022.

Gavi [to 05 Mar 2022]
https://www.gavi.org/
News Releases
No new digest content identified.

GHIT Fund [to 05 Mar 2022]
https://www.ghitfund.org/newsroom/press
No new digest content identified.

Global Fund [to 05 Mar 2022]
News & Stories
Introducing Project STELLAR
04 March 2022
Diagnostics play an essential role in the fight against COVID-19 for effective patient management, infection prevention and control, and disease surveillance. In order to support countries and help them to achieve WHO and Access to COVID-19 Tools Accelerator (ACT-A) targets for COVID-19 diagnostics, the Global Fund has introduced Project STELLAR – Scaling-up Testing and Strengthening Lab Systems.

As one of the centrally managed limited investment (CMLI) projects under the COVID-19 Response Mechanism (C19RM), Project STELLAR has been created to support a group of African countries in maximizing the impact of C19RM resources, to rapidly scale up COVID-19 testing and galvanize longer term strengthening of laboratory systems.

With an initial investment of US$9.86 million, the project will cover the following interventions that should be implemented by December 2023:
- improve national diagnostic governance;
- scale up and increase coverage for COVID-19 testing and surveillance;
- and strengthen data management.
Before it can wreak havoc in human cells, the virus that causes COVID-19 must hide the tip of its genetic material. By delving into how the virus puts on this disguise, researchers have identified a unique way to fight it.

**Steven Deeks: What We Know—or Mostly Don’t Know—about Long COVID**
Ukraine: Amid mounting human cost, parties must uphold international humanitarian law
Statement by ICRC President Peter Maurer, "We are seeing a devastating humanitarian crisis unfold in Ukraine.

04-03-2022 | News release

'Whether Afghanistan, Syria or Ukraine: IHL is the line between barbarity and our common humanity' - ICRC President Peter Maurer
This statement was delivered by Peter Maurer, President of the International Committee of the Red Cross, on the 1 March 2022 at the High Level Segment of the 49th Session of the Human Rights Council.

01-03-2022 | Statement

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC  [to 05 Mar 2022]
Selected Press Releases, Announcements
01/03/2022
Red Cross Red Crescent humanitarian leaders agree on a road map to alleviate the suffering in MENA

01/03/2022
International Red Cross and Red Crescent Movement appeals for 250 million Swiss francs to assist people affected by Ukraine conflict

28 February 2022
Red Cross providing life-saving assistance for hundreds of thousands displaced from Ukraine

Institut Pasteur  [to 05 Mar 2022]
Press Documents
No new digest content identified.

IOM / International Organization for Migration [to 05 Mar 2022]
IOM Ukraine Response Update

03 Mar 2022

IOM and AU Sign New 3-Year Agreement to Strengthen Migration Policies and Frameworks in Africa

01 Mar 2022

IOM Scales Up Response to Ukraine Crisis and Appeals for Inclusive Protection Measures

ISC / International Science Council [to 05 Mar 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Statements and resources on the current conflict in Ukraine
01.03.2022

IVAC [to 05 Mar 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
March 2022

IVI [to 05 Mar 2022]
http://www.ivi.int/
IVI News & Announcements
No new digest content identified.

Johns Hopkins Center for Health Security [to 05 Mar 2022]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

MSF/Médecins Sans Frontières [to 05 Mar 2022]
http://www.msf.org/
Latest [Selected Announcements]
War in Ukraine
 Civilians must be allowed safe passage out of dire conditions in Mariupol
Project Update 5 Mar 2022

War in Ukraine

Accessing areas most affected by fighting in Ukraine
Interview 3 Mar 2022

Madagascar

Cyclones cut people off from healthcare in eastern Madagascar
Project Update 2 Mar 2022

South Sudan

Access to medical care undermined following robbery of MSF staff in Yei
Press Release 1 Mar 2022

Ukraine

MSF mobilises response in Ukraine and nearby countries as conflict escalates
Project Update 1 Mar 2022

National Academy of Sciences - USA [to 05 Mar 2022]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 05 Mar 2022]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates

Vaccines Federal Implementation Plan 2021-2025

On Wednesday March 2, 2022, the U.S. Department of Health and Human Services (HHS) published a Request for Information (RFI) to solicit stakeholder written public comments on the draft Vaccines Federal Implementation Plan 2021-2025- PDF*. HHS values input from all stakeholders and will take all public comments into consideration before finalizing this document.

We encourage your input or comments and ask that you circulate this information to others who may also wish to provide comments. Information about how to provide written public comment is found on HHS.gov and the deadline for submissions is 5 p.m. EST Tuesday March 29, 2022.

The Vaccines Federal Implementation Plan is a companion document to the Vaccines National Strategic Plan 2021-2025 published in January 2021. This plan outlines the federal government’s broad national vaccination goals and offers a framework to eliminate vaccine-preventable diseases through safe and effective vaccination over the lifespan, for both federal agencies and external partners.

The implementation plan focuses on the specific actions that federal agencies can take to further those same national vaccination goals.

NIH [to 05 Mar 2022]
News Releases
No new digest content identified.
COVID-19 death toll four times higher in lower-income countries than rich ones

3 March 2022

3 million people died since the Omicron variant emerged, shattering perceptions that the pandemic is over.

The COVID-19 death toll has been four times higher in lower-income countries than in rich ones, according to a new report published today by Oxfam on behalf of the People’s Vaccine Alliance as the world marks two years since the World Health Organization declared the pandemic.

While the pandemic has been devastating for rich countries like the US and the UK, the world’s poorest countries have been hardest hit, with women and children bearing a disproportionate burden. Lack of testing and reporting means that very large numbers of deaths due to COVID-19 go unreported, especially in the poorest countries. Modelling using measures of excess deaths estimates that 19.6 million people have died because of COVID-19, over three times the official death toll. Based on this analysis, Oxfam calculated that for every death in a high-income country, an estimated four other people have died in a low or lower-middle income country. On a per capita basis, deaths in low and lower middle-income countries are 31 percent higher than high income countries.

Oxfam also calculated that three million COVID-19 deaths have occurred in the three months since the Omicron variant emerged. The figure shatters perceptions that Omicron’s milder illness means the pandemic is coming to an end, as the more contagious variant tears through unvaccinated populations. By some estimates, over half of humanity is set to have been infected with COVID-19 by the end of March 2022. While most cases will be mild, the sheer number of cases means that numbers of deaths remain high.

The report also outlines that:
:: Every minute, four children around the world have lost a parent or caregiver to COVID. In India alone, more than two million children lost a caregiver.
:: Women have been 1.4 times more likely to drop out of the labour force than men because of the pandemic.
:: 99 percent of humanity is worse off because of COVID-19, 160 million people have been pushed into poverty, and 137 million people have lost their jobs...
PATH partners with AstraZeneca and Qure.ai to increase lung cancer detection in low-and-middle income countries
March 3, 2022 by PATH
The three organizations will collaborate to apply an innovative artificial intelligence (AI) technology in the interpretation of radiology images to increase early detection of lung cancer and ultimately reduce mortality rates across emerging markets.

Sabin Vaccine Institute [to 05 Mar 2022]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

UNAIDS [to 05 Mar 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
3 March 2022
Engaging the EU in the Global Partnership on Zero Discrimination Day

1 March 2022
The case for anti-discrimination legislation in Jamaica

1 March 2022
"An HIV diagnosis should not be a guilty verdict—it’s just a diagnosis"

UNHCR Office of the United Nations High Commissioner for Refugees [to 05 Mar 2022]
Selected News Releases, Announcements
News Comment: UNHCR welcomes EU decision to offer Temporary Protection to Refugees fleeing Ukraine
This news comment is attributable to Pascale Moreau, Director of the Bureau for Europe, UNHCR
4 Mar 2022

UNHCR seeks US$205 million to deliver life-saving assistance to over 1.6 million people affected by the northern Ethiopia conflict
4 Mar 2022

News Comment: 1 million refugees have fled Ukraine in a week
This Statement is attributed to the UN High Commissioner for Refugees Filippo Grandi
3 Mar 2022

UNHCR highlights great progress on refugee vaccine inclusion but inequities hamper rollout
2 Mar 2022

UNHCR mobilizing to aid forcibly displaced in Ukraine and neighbouring countries
News Comment: UNHCR warns of increasing violence and human rights violations at European borders
This statement is attributed to UN High Commissioner for Refugees Filippo Grandi.
21 Feb 2022

UNICEF [to 05 Mar 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release
03/03/2022
One week into conflict in Ukraine, half a million children become refugees
GENEVA, 3 March 2022 ––, The conflict in Ukraine, now in its second week, is exacting a harrowing toll on children, UNICEF warned today. Millions of children could be caught up in the violence as the fighting intensifies in and around the country’s major urban centres. Children are especially vulnerable to being injured or killed when weapons and explosive munitions are...

Remarks
03/01/2022
UNICEF Executive Director Catherine Russell’s remarks at the Joint Launch of the Humanitarian Flash Appeal and Regional Refugee Response Plan, Ukraine
NEW YORK, 1 March 2022 ––, "The situation facing children and families caught up in the escalating conflict in Ukraine grows worse by the minute. "The fighting is moving closer to civilian populations – closer to children’s homes and schools, to hospitals and orphanages. "Damage to infrastructure has left hundreds of thousands of people without safe water and...

Statement
02/28/2022
Statement by UNICEF Executive Director Catherine Russell calling for a suspension of hostilities to carry out urgent humanitarian action in Ukraine
NEW YORK, 28 February 2022 –, "The situation for children caught up in the conflict in Ukraine grows worse by the minute. “We are receiving reports of hospitals, schools, water and sanitation facilities and orphanages under fire. Explosive weapons in populated areas and explosive remnants of war are real and present dangers for the children of Ukraine. “Children have been...

Unitaid [to 05 Mar 2022]
https://unitaid.org/
Featured News
03 March 2022
Unitaid statement on WHO guidelines for COVID-19 antiviral molnupiravir
Geneva – Unitaid today welcomes the conditional recommendation from the World Health Organization (WHO) on the use of molnupiravir to treat adult patients with mild to moderate COVID-19 at highest risk of developing severe forms of the disease.

Oral outpatient treatments are potential gamechangers in the management of COVID-19. They are critical in the global response to the pandemic, with a potential to save lives and ease the pressure on healthcare systems, and an important step toward realizing the promise of test-and-treat strategies in decentralized settings.

Molnupiravir is the first oral antiviral for non-hospitalized mild-to-moderate COVID-19 patients to be recommended by WHO, bringing an additional treatment option to the COVID-19 clinical care package...

---

Vaccine Equity Cooperative [nee Initiative]  [to 05 Mar 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin]  [to 05 Mar 2022]
https://www.vaccineacceptance.org/
Announcements
No new digest content identified.

Vaccine Confidence Project  [to 05 Mar 2022]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 05 Mar 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
News
No new digest content identified.

Wellcome Trust  [to 05 Mar 2022]
https://wellcome.ac.uk/news
News. Opinion, Reports
Opinion
Author - Alan Dangour
Five things the latest IPCC report tells us about climate change and health
4 March 2022

The Wistar Institute  [to 05 Mar 2022]
Press Releases
WFPHA: World Federation of Public Health Associations  [to 05 Mar 2022]
https://www.wfpha.org/
Latest News - Blog
What Is Leadership in the Context of the COVID-19 Pandemic?
Mar 4, 2022
What Is Leadership in the Context of the COVID-19 Pandemic? A Reflection by Public Health Leadership Coalition’s Member – Prof. Luís Eugênio de Souza Leadership can be defined as the collection of competences – knowledge, skills and aptitudes –...

World Bank  [to 05 Mar 2022]
Selected News, Announcements
World Bank Group Statement on Russia and Belarus
WASHINGTON, March 2, 2022—The World Bank Group today released the following statement on its programs in Russia and Belarus: “The World Bank Group has not approved any new loans to or investments in Russia... Date: March 02, 2022 Type: Statement

Nearly 2.4 Billion Women Globally Don’t Have Same Economic Rights as Men
Despite Pandemic, 23 Countries Improved Laws to Advance Women’s Economic Inclusion in 2021
WASHINGTON, Mar. 1, 2022 – Around 2.4 billion women of working age are not afforded equal economic opportunity... Date: March 01, 2022 Type: Press Release

Joint IMF-World Bank Group Statement on the War in Ukraine
WASHINGTON, Mar. 1, 2022 – International Monetary Fund (IMF) Managing Director Kristalina Georgieva and World Bank Group President David Malpass today issued the following statement on the war in... Date: March 01, 2022 Type: Statement

World Customs Organization – WCO  [to 05 Mar 2022]
http://www.wcoomd.org/
Latest News – Selected Items
04 March 2022
WCO holds a further series of webinars to improve Customs’ awareness of COVID-19 vaccines
On 15 February 2022, the World Customs Organization (WCO) successfully held its 9th series of webinars aimed at improving Customs administrations’ awareness of counterfeit COVID-19-related goods, in collaboration with high-level representatives from Novavax. These webinars are among the measures taken to ensure thorough implementation by the Secretariat of the WCO Covid-19 Action Plan. The Action Plan was developed shortly after the adoption of the Resolution on the Role of Customs in Facilitating the Cross-Border Movement of Situational...
Critical Medicines and Vaccines, as a temporary and overarching priority in the Implementation Plan 2021-2002 for the WCO Strategic Plan.

The latest webinars were designed to provide Customs with knowledge of the essential characteristics and specifications of the Nuvaxovid COVID-19 vaccine for emergency use. In December 2021, the World Health Organization (WHO) issued an emergency use listing (EUL) for Nuvaxovid, following its assessment and approval by the European Medicines Agency (EMA).

The knowledge gained during these webinars will ensure that Customs administrations are better equipped to identify trafficking in genuine and counterfeit COVID-19 vaccines...

World Organisation for Animal Health (OIE)  [to 05 Mar 2022]
https://www.oie.int/en/media/news/
Press Releases, Statements
World leaders and experts call for action to protect the environment from antimicrobial pollution
Joint Press Release 2 March 2022
[See Perspectives above for detail]

WTO - World Trade Organisation [to 05 Mar 2022]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
No new digest content identified.

ARM [Alliance for Regenerative Medicine] [to 05 Mar 2022]
Selected Press Releases
No new digest content identified.

BIO [to 05 Mar 2022]
Press Releases, Letters, Testimony, Comments [Selected]
BIO Joins Efforts to Aid in Humanitarian Relief in Ukraine
March 2, 2022

DCVMN – Developing Country Vaccine Manufacturers Network [to 05 Mar 2022]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 05 Mar 2022]
https://internationalbiotech.org/news/
News
As the situation in Ukraine continues to cause unimaginable suffering, our thoughts are with the people in Ukraine. Overcoming the challenges that this unprecedented humanitarian crisis poses for patients is our main concern. We are supporting the efforts of our sister regional organization – EFPIA – to ensure vital medicines reach the people who need them most and the health needs of the many thousands of people already displaced by the crisis are met.

“The research-based pharmaceutical industry in Europe stands in solidarity with the people of Ukraine. We condemn the invasion of their country and express our sorrow at the suffering it has caused. As an industry dedicated to saving and improving lives, we stand for peace.

“Our first priority is to ensure that medicines reach the patients that need them in Ukraine, in the neighbouring EU Member States, in Russia and in other countries where access to medicines may be negatively impacted. We call on all parties to facilitate the safe passage of medicines and vaccines to those in need.

“As a health-based industry and part of the wider EU healthcare community, we will work together to address the health needs of all those affected by this war, in Ukraine and in neighbouring countries as part of the wider humanitarian relief effort.

“Our Member Companies and Associations are offering humanitarian support both in Ukraine and for the emerging refugee crisis in neighbouring EU Member States. This includes in kind donations of medical supplies and financial support to NGOs.”

The contributions/actions of individual biopharma organizations below are available at the link above:
AstraZeneca, Boehringer Ingelheim, Chiesi, Ipsen, Lilly, Merck, Novo Nordisk, Roche, Servier, Bayer, Bristol Myers Squibb, GSK, Leem, Lundbeck, Novartis, Pfizer, Sanofi

R&D-based pharmaceutical industry’s innovative partnerships to meet urgent global supply needs
01 March 2022
The examples in this report highlight a few selected collaborations with IFPMA companies. According to Airfinity data, as of March 2022 at least 368 manufacturing and production agreements for COVID-19 vaccines - of which 326 agreements involving some sort technology transfer- around the globe were made public.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.
Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Emergencies
:: Organization Announcements
:: Journal Watch

Milestones - Perspectives

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 1
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 24, Number 2: E107-163  Feb 2022
Tactical Health and Law Enforcement

Tactical health involves providing field-based clinical support to law enforcement operations during frontline crisis interventions and prehospital emergency care. Health professional skill can inform individual officers’ occupational health maintenance and help agents of the state navigate primary and secondary trauma and posttrauma experiences in field- and clinic-based settings. Tactical health expertise can also inform department- and agency-level policies, decisions, and responses to community health and safety threats. Ethical questions considered in this issue focus on the nature and scope of health professionals’ collaborations with law enforcement personnel during and following critical event preparation and responses.

American Journal of Infection Control
March 2022 Volume 50 Issue 3 p243-366
http://www.ajicjournal.org/current

Major Articles

How many lives do COVID vaccines save? Evidence from Israel
Ronen Arbel, Candace Makeda Moore, Ruslan Sergienko, Joseph Pliskin
Published online: December 28, 2021
p258-261

Factors and reasons associated with low COVID-19 vaccine uptake among highly hesitant communities in the US
Saif Khairat, Baiming Zou, Julia Adler-Milstein
Published online: January 04, 2022
p262-267

Facilitators of COVID-19 vaccine acceptance among Black and Hispanic individuals in New York: A qualitative study
Zainab Toteh Osakwe, Jennel C. Osborne, Nonso Osakwe, Ana Stefancic
Published online: November 15, 2021

American Journal of Preventive Medicine
March 2022 Volume 62 Issue 3 p307-472
https://www.ajpmonline.org/current

Research Articles

Parental Vaccine Hesitancy and Association With Childhood Diphtheria, Tetanus Toxoid, and Acellular Pertussis; Measles, Mumps, and Rubella; Rotavirus; and Combined 7-Series Vaccination
Kimberly H. Nguyen, Anup Srivastav, Megan C. Lindley,...Stacie M. Greby, James Lee, James A. Singleton
Published online: December 07, 2021
p367-376

Human Papillomavirus Vaccine Impact on Cervical Precancers in a Low-Vaccination Population
Research Letters

Public Knowledge and Attitudes Toward Clinical Trials in the COVID-19 Era
Eshan U. Patel, Xianming Zhu, Thomas C. Quinn, Aaron A.R. Tobian
Published online: October 07, 2021
p469-471

American Journal of Public Health
March 2022  112(3)
http://ajph.aphapublications.org/toc/ajph/current
PERSPECTIVES
Nurturing Innovation at the Roots: The Success of COVID-19 Vaccination in American Indian and Alaska Native Communities
Emily E. Haroz, Christopher G. Kemp, Victoria M. O’Keefe, Katherine Pocock, David R. Wilson, Loretta Christensen, Melissa Walls, Allison Barlow and Laura Hammitt
112(3), pp. 383–387

NOTES FROM THE FIELD
COVID-19 Vaccine Distribution in a Community With Large Numbers of Immigrants and Refugees
Brett Malone, Esther Kim, Rachel Jennings, Rainer A. Pacheco and Alex Kieu
112(3), pp. 393–396

NOTES FROM THE FIELD
A Rapid Survey of State and Territorial Public Health Partnerships With Faith-Based Organizations to Promote COVID-19 Vaccination
Scott Santibañez, Ashley Ottewell, Paris Harper-Hardy, Elizabeth Ryan, Heidi Christensen and Nathaniel Smith
112(3), pp. 397–400

RESEARCH
COVID-19–Related Discrimination Among Racial/Ethnic Minorities and Other Marginalized Communities in the United States
Paula D. Strassle, Anita L. Stewart, Stephanie M. Quintero, Jackie Bonilla, Alia Alhomsi, Verónica Santana-Ufret, Ana I. Maldonado, Allana T. Forde and Anna María Nápoles
112(3), pp. 453–466
BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 05 Mar 2022)
Investigating the intention to receive the COVID-19 vaccination in Macao: implications for vaccination strategies
Understanding the intention of receiving COVID-19 vaccines is important to inform effective vaccination strategies. This study aimed to investigate such intention, identify the key influencing factors, and det...
Authors: Carolina Oi Lam Ung, Yuanjia Hu, Hao Hu and Ying Bian
Citation: BMC Infectious Diseases 2022 22:218
A qualitative descriptive study of providers’ perspectives on human papillomavirus vaccine administration among Latino/a adolescents in South Texas clinics: barriers and facilitators

South Texas Latinas experience higher cervical cancer incidence and mortality compared to Latinas nationwide. Despite the availability of effective human papillomavirus vaccines, South Texas Latino/a adolescent...

Authors: Daisy Y. Morales-Campos, Bertha E. Flores, Erin Donovan, Suzanne Burdick, Deborah Parra-Medina and Jessica A. Kahn

Citation: BMC Public Health 2022 22:443
Content type: Research
Published on: 5 March 2022
Location, location, location: a discrete choice experiment to inform COVID-19 vaccination programme delivery in the UK
Large-scale vaccination is fundamental to combatting COVID-19. In March 2021, the UK’s vaccination programme had delivered vaccines to large proportions of older and more vulnerable population groups; however, ...
Authors: Robert McPhedran, Natalie Gold, Charlotte Bemand, Dale Weston, Rachel Rosen, Robert Scott, Tim Chadborn, Richard Amlôt, Max Mawby and Ben Toombs
Citation: BMC Public Health 2022 22:431
Content type: Research
Published on: 4 March 2022

Longitudinal changes in COVID-19 vaccination intent among South African adults: evidence from the NIDS-CRAM panel survey, February to May 2021
COVID-19 vaccine hesitancy has threatened the ability of many countries worldwide to contain the pandemic. Given the severe impact of the pandemic in South Africa and disruptions to the roll-out of the vaccine...
Authors: Ronelle Burger, Timothy Köhler, Aleksandra M. Golos, Alison M. Buttenheim, René English, Michele Tameris and Brendan Maughan-Brown
Citation: BMC Public Health 2022 22:422
Content type: Research
Published on: 2 March 2022

BMC Research Notes
http://www.biomedcentral.com/bmcresearchnotes/content
(Accessed 05 Mar 2022)
[No new digest content identified]

BMJ Evidence-Based Medicine
February 2022 - Volume 27 - 1
https://ebm.bmj.com/content/27/1
[Reviewed earlier]

BMJ Open
March 2022 - Volume 12 - 3
https://bmjopen.bmj.com/content/12/3
Elise Tessier, Yuma Rai, Eleanor Clarke, Anissa Lakhani, Camille Tsang, Ashley Makwana, Heather Heard, Tim Rickeard, Shreya Lakhani, Partho Roy, Michael Edelstein, Mary Ramsay, Jamie Lopez-Bernal, Joanne White, Nick Andrews, Colin N J Campbell, Julia Stowe

Bulletin of the World Health Organization
Benchmarks

**The RTS,S vaccine—a chance to regain the upper hand against malaria?**

Photini Sinnis, David A. Fidock

Malaria is estimated by the World Health Organization (WHO) to have killed 627,000 individuals worldwide in 2020, with nearly 80% of deaths in African children younger than five. The recent WHO approval of the RTS,S/AS01 vaccine, which targets Plasmodium falciparum pre-erythrocytic stages, provides hope that its use combined with other interventions can help reverse the current malaria resurgence.

Commentary

**Basic science under threat: Lessons from the Skirball Institute**

Agnel Sfeir, et al

Support for basic science has been eclipsed by initiatives aimed at specific medical problems. The latest example is the dismantling of the Skirball Institute at NYU School of Medicine. Here, we reflect on the achievements and mission underlying the Skirball to gain insight into the dividends of maintaining a basic science vision within the academic enterprises.

Child Care, Health and Development

Volume 48, Issue 2, Pages: 177-357 March 2022

Clinical Pharmacology & Therapeutics

Volume 111, Issue 3 Pages: 519-704 March 2022

**Editorial**

**The Pandemic as a Catalyst for Disruptive Innovation in Clinical Pharmacology**

Kathleen M. Giacomini, Piet H. van der Graaf

Pages: 529-532

First Published: 08 February 2022

**Perspectives**

**US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines**

Hussain S. Lalani, Jerry Avorn, Aaron S. Kesselheim

Pages: 542-544

First Published: 09 July 2021
Science, Innovation, and Society in the Age of Pandemics: Reflections From the Inaugural Sir Alasdair Breckenridge Lecture
Nokuthula Sikhethiwe Kitikiti, Uttara Soumyanarayanan, Silke Vogel, John C. W. Lim
Pages: 548-550
First Published: 11 November 2021

Mini-Review
Open Access
Japan’s Special Approval for Emergency System During the COVID-19 Pandemic
Hideki Maeda
Pages: 551-558
First Published: 25 May 2021

Clinical Therapeutics
December 2021 Volume 43 Issue 12 p2041-2172
http://www.clinicaltherapeutics.com/current
[Reviewed earlier]

Clinical Trials
Volume 19 Issue 1, February 2022
https://journals.sagepub.com/toc/ctja/19/1
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 05 Mar 2022]
The impact of the COVID-19 pandemic on the mental health of Rohingya refugees with pre-existing health problems in Bangladesh
Mental disorders among refugees have been well explored in several studies. However, longitudinal studies on the impact of the pandemic on refugee populations are widely lacking. This study was designed to exa...
Authors: Somen Palit, Huifang Yang, Jiangping Li, Md. Abdullah Saeed Khan and Mohammad Jahid Hasan
Citation: Conflict and Health 2022 16:10
Content type: Research

Contemporary Clinical Trials
Volume 113 February 2022
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/113/suppl/C
[Reviewed earlier]

The CRISPR Journal
Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
April 2022 - Volume 35 - Issue 2
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[New issue; No digest content identified]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 22, Issue 1  Pages: 1-62  March 2022
https://onlinelibrary.wiley.com/toc/14718847/current
EDITIORIAL
The evolution of bioethics in the global south
Pages: 3
First Published: 03 March 2022

Development in Practice
Volume 32, Issue 1, 2021
http://www.tandfonline.com/toc/cdip20/current
Articles
The role of Indigenous traditional institutions in fighting against the COVID-19 pandemic in Ghana
Vincent Ekow Arkorful
Pages: 107-111
Published online: 02 Dec 2021

Disaster Medicine and Public Health Preparedness
Volume 15 - Issue 6 - December 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]
Disasters
Volume 46, Issue 1  Pages: 1-298  January 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23  Issue 2  3 February 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 28, Number 2—February 2022
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 37  December 2021
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[New issue; No digest content identified]

Ethics & Human Research
https://onlinelibrary.wiley.com/toc/25782363/current
[Reviewed earlier]

Ethics & International Affairs
Winter 2021 (35.4)  |  December 2021
https://www.ethicsandinternationalaffairs.org/2021/winter-2021-35-4/
TABLE OF CONTENTS
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 20  February 2022
Global Health: Science and Practice (GHSP)
Vol. 10, No. 1  February 28, 2022
http://www.ghspjournal.org/content/current

EDITORIALS
COVID-19 Vaccine Hesitancy
Doug Storey
Global Health: Science and Practice February 2022, 10(1):e2200043; https://doi.org/10.9745/GHSP-D-22-00043
Improving access to accurate information on vaccines and vaccination, increasing trust in reliable information sources, and counteracting misinformation can go a long way toward improving vaccination decision making.

COMMENTARIES
Open Access
Maintaining Polio-Free Status in Indonesia During the COVID-19 Pandemic
Despite the negative impact that the COVID-19 pandemic has had on polio eradication efforts, ensuring the high coverage of polio immunization and high performance of surveillance are essential to maintaining Indonesia’s polio-free status and the reaching the 2023 global polio eradication target.

**Role of Information Sources in Vaccination Uptake: Insights From a Cross-Sectional Household Survey in Sierra Leone, 2019**


Global Health: Science and Practice February 2022, 10(1):e2100237; https://doi.org/10.9745/GHSP-D-21-00237

Our findings suggest that health workers and faith leaders are important sources of information to deliver vaccination messages, given their strong association with vaccination confidence and uptake. In this context, vaccination promotion efforts that integrate faith leaders and health workers may help increase vaccination uptake.

**FIELD ACTION REPORTS**

**Key Factors Influencing Use of Immunization Cost Evidence in Country Planning and Budgeting Processes: Experiences From Indonesia, Tanzania, and Vietnam**

Annette Ozaltin, Kelsey Vaughan, Kassimu Tani, Fatuma Manzi, Vu Quynh Mai, Hoang Van Minh, Soewarta Kosen, Lora Shimp, Logan Brenzel and Laura Boonstoppel

Global Health: Science and Practice February 2022, 10(1):e2100264; https://doi.org/10.9745/GHSP-D-21-00264

The evidence to policy and practice facilitated process represents a journey that countries and their development partners can embark on to increase the likelihood that health policy makers will use cost evidence for policy making and planning.

**REVIEWS**

**Implementation Approaches for Introducing and Overcoming Barriers to Hepatitis B Birth-Dose Vaccine in sub-Saharan Africa**

Alix Boisson, Varun Goel, Marcel Yotebieng, Jonathan B. Parr, Bruce Fried and Peyton Thompson

Global Health: Science and Practice February 2022, 10(1):e2100277; https://doi.org/10.9745/GHSP-D-21-00277

We discuss determinants of hepatitis B birth-dose vaccine uptake in sub-Saharan Africa countries at the policy, facility, and community levels and propose solutions to known barriers of hepatitis B vaccine introduction in low- and middle-income countries.
COVAX, vaccine donations and the politics of global vaccine inequity
Authors: Antoine de Bengy Puyvallée and Katerini Tagmatarchi Storeng
Citation: Globalization and Health 2022 18:26
Content type: Research
Published on: 5 March 2022
In 2021, donor countries, the pharmaceutical industry, and the COVAX initiative promoted vaccine donation or “dose-sharing” as a main solution to the inequitable global distribution of Covid-19 vaccines. COVAX positioned itself as a global vaccine-sharing hub that promised to share doses “equitably, effectively and transparently,” according to rational criteria overseen by independent scientists. This article provides a critical analysis of the principles and practice of “dose-sharing,” showing how it reveals the politics at play within COVAX.
Much health communication during the COVID-19 pandemic has been designed to persuade people more than to inform them. For example, messages like “masks save lives” are intended to compel people to wear face ma...

Authors: Andrew D. Oxman, Atle Fretheim, Simon Lewin, Signe Flottorp, Claire Glenton, Arnfinn Helleve, Didrik Frimann Vestrheim, Bjørn Gunnar Iversen and Sarah E. Rosenbaum

Citation: Health Research Policy and Systems 2022 20:28
Content type: Commentary
Published on: 5 March 2022

**Domains and processes for institutionalizing evidence-informed health policy-making: a critical interpretive synthesis**

While calls for institutionalization of evidence-informed policy-making (EIP) have become stronger in recent years, there is a paucity of methods that governments and organizational knowledge brokers can use t...

Authors: Tanja Kuchenmüller, Laura Boeira, Sandy Oliver, Kaelan Moat, Fadi El-Jardali, Jorge Barreto and John Lavis

Citation: Health Research Policy and Systems 2022 20:27
Content type: Review
Published on: 4 March 2022

**Human Gene Therapy**
Volume 33, Issue 3-4 / February 2022
https://www.liebertpub.com/toc/hum/33/3-4
[Reviewed earlier]

**Humanitarian Practice Network**
https://odihpn.org/
*Online Article*
[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 17, Issue 11, 2021
https://www.tandfonline.com/toc/khvi20/current
[Reviewed earlier]

**Immunity**
Feb 08, 2022 Volume 55 Issue 2 p185-376
https://www.cell.com/immunity/current
[Reviewed earlier]

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/
[Accessed 05 Mar 2022]
International Health
Volume 14, Issue 2, March 2022
https://academic.oup.com/inthealth/issue/14/2

**REVIEW ARTICLES**

**International stem cell tourism: a critical literature review and evidence-based recommendations**
Samantha Lyons, Shival Salgaonkar, Gerard T Flaherty
International Health, Volume 14, Issue 2, March 2022, Pages 132–141,
https://doi.org/10.1093/inthealth/ihab050

International Human Rights Law Review
Volume 10 (2021): Issue 2 (Dec 2021)
https://brill.com/view/journals/hrlr/10/2/hrlr.10.issue-2.xml
[Reviewed earlier]

International Journal of Community Medicine and Public Health
Vol 9, No 1 (2022) January 2022
https://www.ijcmph.com/index.php/ijcmph/issue/view/84
[Reviewed earlier]

International Journal of Epidemiology
Volume 51, Issue 1, February 2022
https://academic.oup.com/ije/issue
[New issue; No digest content identified]

International Journal of Human Rights in Healthcare
Volume 14 Issue 5  2021
https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/5
Table of Contents
[Reviewed earlier]

JAMA
March 1, 2022, Vol 327, No. 9, Pages 799-885
https://jamanetwork.com/journals/jama/currentissue
Viewpoint

**Vaccination for Dengue Prevention**
Laura E. Adams, DVM, MPH; Steve Waterman, MD, MPH; Gabriela Paz-Bailey, MD, MSc, PhD

This Viewpoint from the CDC summarizes the recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of the FDA-licensed live-attenuated dengue vaccine in the US.

**JAMA Network**

**COVID-19 Update  March 5, 2022**
These articles on COVID-19 were published across the JAMA Network in the last week.

**JAMA Pediatrics**
February 2022, Vol 176, No. 2, Pages 115-212
https://jamanetwork.com/journals/jamapediatrics/currentissue
[Reviewed earlier]

**JBI Evidence Synthesis**
February 2022 - Volume 20 - Issue 2
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[New issue; No digest content identified]

**Journal of Adolescent Health**
March 2022 Volume 7 0Issue 3 p351-516
https://www.jahonline.org/current

**Commentary**

**Lessons Learned From Human Papillomavirus Vaccination to Increase Uptake of Adolescent COVID-19 Vaccination**
Grace Ryan, Natoshia M. Askelson, Mary Beth Miotto,...
Published online: December 15, 2021
p359-360

**Original Articles**

**COVID-19 Among Youth in Israel: Correlates of Decisions to Vaccinate and Reasons for Refusal**
Ateret Gewirtz-Meydan, Kim Mitchell, Yaniv Shlomo, Oren Heller, Michal Grinstein-Weiss
Published online: November 23, 2021
p396-402

**Adolescent Health Briefs**

**COVID-19 Vaccination Rates and Attitudes Among Young Adults With Recent Experiences of Homelessness**
Joan S. Tucker, et al.
Published online: November 22, 2021
p504-506
Journal of Artificial Intelligence Research
Vol. 73 (2022)
https://www.jair.org/index.php/jair
[Reviewed earlier]

Journal of Community Health
Volume 47, issue 1, February 2022
https://link.springer.com/journal/10900/volumes-and-issues/47-1
[Reviewed earlier]

Journal of Development Economics
Volume 155  March 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 1-2, February-April 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
March 2022 - Volume 76 - 3
https://jech.bmj.com/content/76/3
Essay
Tuberculosis in times of COVID-19 (17 September, 2021)
Alexandra Jaye Zimmer, Joel Shyam Klington, Charity Oga-Omenka, Petra Heitkamp, Carol Nawina Nyirenda, Jennifer Furin, Madhukar Pai

Journal of Evidence-Based Medicine
Volume 14, Issue 4  Pages: 257-345  December 2021
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 17, Issue 3, 2021
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHGPU)
Current controversy

Bonginkosi Shozi, Tamanda Kamwendo, Julian Kinderlerer, Donrich W Thaldar, Beverley Townsend, Marietjie Botes

Commentary

Is It Time for Coronavirus Disease-2019 Vaccine Mandates?
Henry H. Bernstein, Veronica Valentine McNally, Walter A. Orenstein
Published online: November 13, 2021
p235-237
European Pediatric Societies Call for an Implementation of Regular Vaccination Programs to Contrast the Immunity Debt Associated to Coronavirus Disease-2019 Pandemic in Children

Robert Cohen, Massimo Pettoello-Mantovani, Eli Somekh, Corinne Levy
Published online:

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 05 Mar 2022]
Management of COVID-19 vaccines cold chain logistics: a scoping review
Successful mass vaccination programmes are public health achievements of the contemporary world. While pharmaceutical companies are actively developing new vaccines, and demonstrating results of effectiveness ...
Authors: Mathumalar Loganathan Fahrni, Intan An-Nisaa’ Ismail, Dalia Mohammed Refi, Ahmad Almeman, Norliana Che Yaakob, Kamaliah Md Saman, Nur Farhani Mansor, Noorasmah Noordin and Zaheer-Ud-Din Babar
Citation: Journal of Pharmaceutical Policy and Practice 2022 15:16
Content type: Review
Published on: 2 March 2022

Journal of Public Health Management & Practice
March/April 2022 - Volume 28 - Issue 2
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[New issue; No digest content identified]

Journal of Public Health Policy
Volume 43, issue 1, March 2022
https://link.springer.com/journal/41271/volumes-and-issues/43-1
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
February 2022 Volume 19 Issue 187
https://royalsocietypublishing.org/toc/rsif/current
[New issue; No digest content identified]
Comment

Waning of COVID-19 vaccine effectiveness: individual and public health risk
Vanessa Piechotta, Thomas Harder

Prioritise research on vaccines for pregnant and breastfeeding women
Terra Manca, Françoise Baylis, Flor M Munoz, Karina A Top

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
Lorcan P McGarvey, et al COUGH-1 and COUGH-2 Investigators

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Daniel R Feikin, et al
Open Access
**Lancet Global Health**
Mar 2022 Volume 10 Number 3 e298-e447
https://www.thelancet.com/journals/langlo/issue/current

**Comment**
**COVID-19 vaccine hesitancy in Africa: a call to action**
Polydor Ngoy Mutombo, et al.

**Bridging the gap between science and policy in global health governance**
Olivier Nay, Françoise Barré-Sinoussi

---

**Lancet Infectious Diseases**
Mar 2022 Volume 22 Number 3 p297-426, e66-e100
https://www.thelancet.com/journals/laninf/issue/current

**Editorial**
**Transitioning to endemicity with COVID-19 research**
The Lancet Infectious Diseases

**Comment**
**COVID-19 vaccine inequity, dependency, and production capability in low-income and middle-income countries: the case of Bangladesh**
Abdullah Mahmud-Al-Rafat, et al.

**Articles**
**Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial**
Peter G Kremsner, et al on behalf of the HERALD Study Group

**Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study**
Devashish Desai, et al

**Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study**
Eric J Haas, et al

**Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial**
Mahamadou S Sissoko, et al

**Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial**
Stephen E Goldstone, et al
Editorial
Future pandemics: failing to prepare means preparing to fail
The Lancet Respiratory Medicine

Wanted: better systems for turning evidence into action
The pandemic created a colossal demand for scientific evidence to inform decision-making. Now researchers are mapping out what went wrong and what needs to change.

Nature Biotechnology
Volume 40 Issue 2, February 2022
https://www.nature.com/nbt/volumes/40/issues/2
[Reviewed earlier]
**Nature Communications**
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 05 Mar 2022)
[No new digest content identified]

**Nature Genetics**
Volume 54 Issue 2, February 2022
https://www.nature.com/ng/volumes/54/issues/2
[Reviewed earlier]

**Nature Human Behaviour**
Volume 6 Issue 2, February 2022
https://www.nature.com/nathumbehav/volumes/6/issues/2

*Focus on vaccine inequity*
Equitable distribution of resources to fight COVID-19 is a global challenge. In a collection of research and opinion articles, researchers, public health officials, intellectual property experts, leaders of international organizations, and activists explain how global inequities in COVID-19 vaccine allocation continue fuelling the pandemic, and discuss ways to address these disparities.
[Reviewed earlier]

**Nature Medicine**
Volume 28 Issue 2, February 2022
https://www.nature.com/nm/volumes/28/issues/2
[Reviewed earlier]

**Nature Reviews Genetics**
Volume 23 Issue 3, March 2022
https://www.nature.com/nrg/volumes/23/issues/3

*Review Article* | 26 November 2021

**Navigating the pitfalls of applying machine learning in genomics**
Machine learning is widely applied in various fields of genomics and systems biology. In this Review, the authors describe how responsible application of machine learning requires an understanding of several common pitfalls that users should be aware of (and mitigate) to avoid unreliable results.
Sean Whalen, Jacob Schreiber, Katherine S. Pollard

**Nature Reviews Immunology**
Volume 22 Issue 3, March 2022
https://www.nature.com/nri/volumes/22/issues/3

*Comment* | 10 February 2022

**Modelling vaccination strategies for COVID-19**
Mathematical models have been used to guide strategies for COVID-19 vaccine distribution. But with the emergence of new SARS-CoV-2 variants and waning immunity, how should vaccine distribution be prioritized?
Caroline E. Wagner, Chadi M. Saad-Roy, Bryan T. Grenfell

Nature Reviews Drug Discovery
Volume 21 Issue 2, February 2022
https://www.nature.com/nrd/volumes/21/issues/2
[Reviewed earlier]

New England Journal of Medicine
March 3, 2022 Vol. 386 No. 9
https://www.nejm.org/toc/nejm/medical-journal
Original Articles

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
J. Sadoff and Others

Editorials
Audio Interview: Using Our Covid-19 Experience to Develop Vaccines More Quickly
E.J. Rubin, L.R. Baden, and S. Morrissey

npj Vaccines
https://www.nature.com/npjvaccines/
[Accessed 05 Mar 2022]
Article
02 Mar 2022
Pandemic-response adenoviral vector and RNA vaccine manufacturing
Zoltán Kis, Kyungjae Tak, Cleo Kontoravdi

Pediatrics
Volume 149, Issue 3, March 1, 2022
https://pediatrics.aappublications.org/
Articles
Household Transmission and Clinical Features of SARS-CoV-2 Infections
Huong Q. McLean, PhD, MPH; Carlos G. Grijalva, MD, MPH; Kayla E. Hanson, MPH; Yuwei Zhu, MD, MS; Jessica E. Deyoe, MPH ...

PharmacoEconomics
Volume 40, issue 3, March 2022
Original Research Article
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment
Authors - Gabin F. Morillon, Thomas G. Poder
Open Access
Published: 20 January 2022
Pages: 341 - 354

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 05 Mar 2022)
[No new digest content identified]

PLoS Genetics
https://journals.plos.org/plosgenetics/
(Accessed 05 Mar 2022)
[No new digest content identified]

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 05 Mar 2022)
Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study
Ruth Elizabeth Watkinson, Richard Williams, Stephanie Gillibrand, Caroline Sanders, Matt Sutton
Research Article | published 03 Mar 2022 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003932

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 05 Mar 2022)
[No new digest content identified]

PLoS One
http://www.plosone.org/
[Accessed 05 Mar 2022]
Research Article
Willingness to take COVID-19 vaccination in low-income countries: Evidence from Ethiopia
Christoph Strupat, Zemzem Shigute, Arjun S. Bedi, Matthias Rieger
Research Article | published 03 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0264633

Implementation of a COVID-19 Genomic Surveillance Regional Network for Latin America and Caribbean region
Public opinion concerning governments’ response to the COVID-19 pandemic
Cathy W. S. Chen, Tsai-Hung Fan
Research Article | published 02 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0260062

Vaccination conspiracy beliefs among social science & humanities and STEM educated people—An analysis of the mediation paths
Željko Pavić, Adrijana Šuljok
Research Article | published 01 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0264722

COVID-19 vaccine acceptance and rejection in an adult population in Bosnia and Herzegovina
Adnan Fojnica, Ahmed Osmanovic, Nermin Duzic, Armin Fejzic, Ensar Mekic, Zehra Gromilic, Imer Muhovic, Amina Kurtovic-Kozaric
Research Article | published 28 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0264754

COVID-19 vaccination coverage in deprived populations living in segregated colonies: A nationwide cross-sectional study in Hungary
János Sándor, Ferenc Vincze, Maya Liza Shrikant, László Kőrösi, László Ulicska, Karolina Kósa, Róza Ádány
Research Article | published 28 Feb 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0264363

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 05 Mar 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
February 8, 2022 | vol. 119 | no. 6
https://www.pnas.org/toc/pnas/119/6
Research Article February 1, 2022 Open Access
A 680,000-person megastudy of nudges to encourage vaccination in pharmacies
Encouraging vaccination is a pressing policy problem. To assess whether text-based reminders can encourage pharmacy vaccination and what kinds of messages work best, we conducted a megastudy. We randomly assigned 689,693 Walmart pharmacy patients to ...
Katherine L. Milkman, Linnea Gandhi, […] Angela L. Duckworth
Prehospital & Disaster Medicine
Volume 37 - Issue 1 - February 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 155   February 2022
[Reviewed earlier]

Proceedings of the Royal Society B
09 March 2022   Volume 289   Issue 1970
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 203   Pages 1-130 (February 2022)
[Reviewed earlier]

Public Health Ethics
Volume 14, Issue 3, November 2021
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 137 Issue 2, March/April 2022
https://journals.sagepub.com/toc/phrg/137/2
Commentary
**Ensuring Equitable COVID-19 Vaccination for People With Disabilities and Their Caregivers**
Lisa D. Wiggins, PhD, Harriet Jett, JD, MPA, Jennifer Meunier, MPH
First Published December 30, 2021; pp. 185–189

**Ethical Principles in Personal Protective Equipment Inventory Management Decisions and Partnerships Across State Lines During the COVID-19 Pandemic**
Tazim Merchant, BA, Sean Hormozian, BS, Roger S. Smith, BS, Tricia Pendergrast, BA, Aliza Siddiqui, BS, Zhaoyang Wen, BA, Mark Sheldon, PhD
First Published December 30, 2021; pp. 208–212

Brief Report
Surveillance of COVID-19 Vaccination in Nursing Homes, United States, December 2020–July 2021
First Published February 5, 2022; pp. 239–243

Qualitative Health Research
Volume 32 Issue 4, March 2022
https://journals.sagepub.com/toc/qhra/current
Research Articles
How Perceptions of Responsibility and Affective Consequences Influence Parents’ Digital Media Engagement in Relation to Human Papillomavirus Vaccination
Maja Nordtug
First Published December 29, 2021; pp. 683–693

Research Ethics
Volume 18 Issue 1, January 2022
http://journals.sagepub.com/toc/reab/current
Topic Piece
Reshaping the review of consent so we might improve participant choice
Hugh Davieson behalf of the Oxford “A” Research Ethics Committee
First Published September 15, 2021; pp. 3–12

Original Article: Empirical
Recruiting pupils for a school-based eye study in Nigeria: Trust and informed consent concerns
First Published September 8, 2021; pp. 13–23

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 05 Mar 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]
Risk Analysis
Volume 42, Issue 1 January 2022
https://onlinelibrary.wiley.com/toc/15396924/current

Special Issue: Global Systemic Risk and Resilience for Novel Coronavirus in Post-Pandemic Era
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 05 Mar 2022]

Original Research
Understanding the Facilitators and Barriers to COVID-19 Vaccine Uptake Among Teachers in the Sagnarigu Municipality of Northern Ghana: A Cross-Sectional Study
Dubik SD
Published Date: 24 February 2022

Science
Volume 375| Issue 6584| 4 Mar 2022
https://www.science.org/toc/science/current

Policy Forum
A role for funders in fostering China’s research integrity
Li Tang
03 Mar 2022: 979-981
Free
Despite recent progress, challenges remain

Science Translational Medicine
Volume 14| Issue 634| 2 Mar 2022
https://www.science.org/toc/stm/current

Report
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
BY Benjamin L. Sievers et al.

Social Science & Medicine
Volume 292 January 2022
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 05 Mar 2022]
[No new digest content identified]
Theoretical Medicine and Bioethics
Volume 42, issue 3-4, August 2021
*Special Issue: A plea for an experimental philosophy of medicine*
[Reviewed earlier]

Travel Medicine and Infectious Diseases
Volume 45  January–February 2022
[Reviewed earlier]

Tropical Medicine & International Health
Volume 27, Issue 2  Pages: i-iv, 121-216  February 2022
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 40, Issue 7  Pages 967-1060 (11 February 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/7
*Short communication  Open access*
**Adolescents’ attitudes to the COVID-19 vaccination**
W.H.S. Wong, D. Leung, G.T. Chua, J.S.R. Duque, ... Y.L. Lau
Pages 967-969

*Short communication  Open access*
Research articleAbstract only
**Cost-effectiveness of pertussis booster vaccination for preschool children in Japan**
Motoko Tanaka, Reiko Okubo, Shu-Ling Hoshi, Nobuyuki Ishikawa, Masahide Kondo
Pages 1010-1018

*Research article  Open access*
**Variation in influenza vaccine assessment, receipt, and refusal by the concentration of Medicare Advantage enrollees in U.S. nursing homes**
Patience Moyo, Elliott Bosco, Barbara H. Bardenheier, Maricruz Rivera-Hernandez, ... Andrew R. Zullo
Pages 1031-1037

Value in Health
March 2022  Volume 25  Issue 3  p321-472
https://www.valueinhealthjournal.com/current
**THEMED SECTION: ARTIFICIAL INTELLIGENCE**
**The Value of Artificial Intelligence for Healthcare Decision Making—Lessons Learned**
Danielle Whicher, Thomas Rapp
BRIEF REPORT
The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review
Joseph Kazibwe, Adrian Gheorghe, David Wilson, Francis Ruiz, Kalipso Chalkidou, Y-Ling Chi
Published online: October 28, 2021
p385-389

Pre-Print Servers

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 05 Mar 2022]
[No new digest content identified]

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...

Precision recruitment for high-risk participants in a COVID-19 research study
Aziz Mezlini, Eamon Caddigan, Allison Shapiro, Ernesto Ramirez, Helena Kondow-McConaghy, Justin Yang, Kerry DeMarco, Pejman Naraghi-Arani, Luca Foschini
medRxiv 2022.03.03.22271504; doi: https://doi.org/10.1101/2022.03.03.22271504

Impact of Population Mixing Between a Vaccinated Majority and Unvaccinated Minority on Disease Dynamics. Implications for SARS-CoV-2
Ashleigh Tuite, Afia Amoako, David Fisman

Determinants of COVID-19 vaccine acceptability in Mozambique: the role of institutional trust
Bo Hu, Wei Yang, Paul Alexandre Bouanchar, Yolanda Chongo, Jennifer Wheeler, Sergio Chicumbe, Marcos Chissano
medRxiv 2022.03.03.22271828; doi: https://doi.org/10.1101/2022.03.03.22271828
Abstract
Background Vaccination plays an imperative role in protecting public health and preventing avoidable mortality. Yet, the reasons for vaccine hesitancy are not well understood. This study investigates the
factors associated with the acceptability of COVID-19 vaccine in Mozambique. Methods The data came from the three waves of the COVID-19 Knowledge, Attitudes and Practices (KAP) survey which followed a cohort of 1,371 adults in Mozambique over three months (N=3,809). Data collection was through a structured questionnaire using telephone interviewing (CAPI). Multilevel regression analysis was conducted to identify the trajectories of, and the factors associated with COVID-19 vaccine acceptability. Results There was great volatility in COVID-19 vaccine acceptability over time. Institutional trust was consistently and strongly correlated with different measures of vaccine acceptability. There was a greater decline in vaccine acceptability in people with lower institutional trust. The positive correlation between institutional trust and vaccine acceptability was stronger in younger than older adults. Vaccine acceptability also varied by gender and marital status. Conclusions Vaccine acceptability is sensitive to news and information circulated in the public domain. Institutional trust is a central driver of vaccine acceptability and contributes to the resilience of the health system. Our study highlights the importance of health communication and building a trustful relationship between the general public and public institutions in the context of a global pandemic.

**Acute and long-term impacts of COVID-19 on economic vulnerability: a population-based longitudinal study (COVIDENCE UK)**
Anne E Williamson, Florence Tydeman, Alec Miners, Kate Pyper, Adrian R Martineau
medRxiv 2022.03.03.22271835; doi: https://doi.org/10.1101/2022.03.03.22271835

**An observational study of the association between COVID-19 vaccination rates and participation in a vaccine lottery**
Dajung Jun, Anthony Scott
medRxiv 2022.03.02.22271734; doi: https://doi.org/10.1101/2022.03.02.22271734

**Abstract**
Objectives Are financial incentives from entry in a vaccine lottery associated with a higher probability of vaccination for COVID-19? Design A cross-sectional study with adjustment for covariates using logistic regression Setting October and November 2021, Australia. Participants 2,375 respondents of the Taking the Pulse of the Nation Survey Interventions Participation in the Million Dollar Vaccination Lottery Primary and secondary outcome measures The proportion of respondents who had any vaccination, a first dose only, or second dose compared to all other respondents Results Those who participated in the lottery were 2.27 times more likely to be vaccinated after the lottery opened on October 1st than those who did not. This was driven by those receiving second doses. Lottery participants were 1.38 times more likely to receive their first dose after October 1st and 2.31 times more likely to receive their second dose after October 1st. Conclusions Lottery participation is associated with a higher vaccination rate, with this effect dominated by a higher rate of second doses. There is a smaller insignificant difference for those receiving a first dose, suggesting lotteries may not be as effective at reducing vaccine hesitancy, compared to 'nudging' people to get their second dose more quickly.

**Prevalence of Chronic Diseases, Depression, and Stress among U.S. Child Care Professionals during the COVID-19 Pandemic**
medRxiv 2022.03.01.22271717; doi: https://doi.org/10.1101/2022.03.01.22271717
The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
medRxiv 2022.02.27.22271399; doi: https://doi.org/10.1101/2022.02.27.22271399

Racial/Ethnic Disparities in the Observed COVID-19 Case Fatality Rate Among the U.S. Population
L. Philip Schumm, Mihai C. Giurcanu, Kenneth J. Locey, Jean Czerlinski Ortega, Zhenyu Zhang, Robert L. Grossman
medRxiv 2022.03.01.22271708; doi: https://doi.org/10.1101/2022.03.01.22271708

Healthcare services access, use, and barriers among migrants in Europe: a systematic review
Petros Galanis, Koureas Spyros, Olga Siskou, Olympia Konstantakopoulou, Georgios Angelopoulos, Daphne Kaitelidou
medRxiv 2022.02.24.22271449; doi: https://doi.org/10.1101/2022.02.24.22271449

Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications
medRxiv 2021.09.29.21264325; doi: https://doi.org/10.1101/2021.09.29.21264325

Vaccine hesitancy strongly correlates with COVID-19 deaths underreporting
Adam Sobieszek, Miriam Lipniacka, Tomasz Lipniacki
medRxiv 2022.02.27.22271579; doi: https://doi.org/10.1101/2022.02.27.22271579

Genomic surveillance of SARS-CoV-2 in a university community: insights into tracking variants, transmission, and spread of Gamma (P.1) variant
Ilincia I. Ciubotariu, Jack Dorman, Nicole M. Perry, Lev Gorenstein, Jobin J. Kattoor, Abebe A. Fola, Amy Zine, G. Kenitra Hendrix, Rebecca P. Wilkes, Andrew Kitchen, Giovanna Carpi
medRxiv 2022.02.25.22271521; doi: https://doi.org/10.1101/2022.02.25.22271521

SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis
Tracy Beth Hoeg, Allison Krug, Josh Stevenson, John Mandrola
medRxiv 2021.08.30.21262866; doi: https://doi.org/10.1101/2021.08.30.21262866
Wellcome Open Research [to 05 Mar 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 05 Mar 2022]
Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Method Article metrics
Revised
An optimization of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams [version 2; peer review: 1 approved, 1 approved with reservations]
Peer Reviewers Davis Nwakanma; Esther Omuseni and John Waitumbi
Funders
Wellcome Trust
DELTAS Africa Initiative
PATH
National Institute for Health Research
Department for International Development, UK Government
LATEST VERSION PUBLISHED 04 Mar 2022

Research Article metrics AWAITING PEER REVIEW
Pandemic preparedness and responsiveness of research review committees: lessons from review of COVID-19 protocols at KEMRI Wellcome Trust Research Programme in Kenya [version 1; peer review: awaiting peer review]
Alex Hinga, Lisha Jeena, Esther Awuor, Jane Kahindi, Marianne Munene, Samson Kinyanjui, Sassy Molyneux, Vicki Marsh, Dorcas Kamuya
Peer Reviewers Invited
Funders
Wellcome Trust
African Academy of Sciences
PUBLISHED 03 Mar 2022

Research Article metrics AWAITING PEER REVIEW
Health care users’ acceptance of broad consent for storage of biological materials and associated data for research purposes in Uganda [version 1; peer review: awaiting peer review]
Hellen Nansumba, Mugalula Flaviano, Semanda Patrick, Ssewanyana Isaac, Douglas Wassenaar
Peer Reviewers Invited
Think Tanks

**Brookings**
http://www.brookings.edu/
Accessed 05 Mar 2022
Africa in Focus
*How strengthened political engagement can lead to improved health outcomes in Africa*
Jean-Baptiste Nikiema
Tuesday, March 1, 2022

**Center for Global Development**  [to 05 Mar 2022]
https://www.cgdev.org/
Accessed 05 Mar 2022
*Expanding Emergency Vaccine Manufacturing Capacity in Latin America and the Caribbean*
Publication
March 3, 2022
The COVID-19 pandemic has transformed the global vaccine manufacturing landscape, with capacity more than doubling in the past 18 months. Before the pandemic, manufacturers produced an estimated total of five billion vaccine doses each year. In 2021, manufacturers produced 12 billion doses of COVID-19 vaccine, with 1.4 billion doses produced in December alone.

**How Can Latin America and the Caribbean Successfully Expand Emergency Vaccine Manufacturing?**
March 3, 2022
The COVID-19 pandemic has pushed global vaccine manufacturing capacity to new limits and primed the pump for further expansion in regions like Lati
Morgan Pincombe and Javier Guzman

**Chatham House**  [to 05 Mar 2022]
https://www.chathamhouse.org/
Accessed 05 Mar 2022
[No new digest content identified]

**CSIS**
https://www.csis.org/
Accessed 05 Mar 2022
Upcoming Event
Overcoming Gender-Related Barriers to Immunization Services
March 8, 2022

Podcast Episode
Live From Munich: Dr. Seth Berkley: “It is a Security Issue”
March 4, 2022 | By Katherine E. Bliss, J. Stephen Morrison

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 05 Mar 2022
March 1, 2022  News Release
Large Shares of the Public Worry about the Consequences of Both Ending and Keeping COVID-19 Restrictions, with Partisans Largely Split on Which Direction is Most Concerning
As federal, state, and local authorities move to roll back COVID-19 restrictions, a new KFF COVID-19 Vaccine Monitor survey finds many people ready to get back to normal but a public also nervous about the potential consequences. Large shares of the public are worried about the implications of both keeping...

Rand  [to 05 Mar 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
[No new digest content identified]

*      *      *      *
*      *      *      *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

:::::

Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation, The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.
CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.